

Objectives: Our primary objective is to determine whether hBD-2 levels differ between children with IgAV and healthy controls. Our secondary aim was to compare hBD-2 levels in children with IgAV with gastrointestinal (GI) and/or genitourinary (GU) involvement and those with skin and joint involvement only.

Methods: The study included 45 children diagnosed with IgAV who presented to our pediatric rheumatology clinic and 35 healthy controls. Blood samples for hBD-2 measurement were collected from patients prior to steroid administration, if used. Healthy controls had no infections and had not used antibiotics or steroids in the week prior to sampling. Patients with IgAV were divided into two groups according to steroid use and baseline laboratory parameters and hBD-2 levels were compared. Patients were also grouped by age (<10 and ≥10 years) to compare hBD-2 levels. Human Beta Defensin-2 ELISA kits were provided by E-Lab Science™. We used SPSS v28 for statistical analysis.

Results: IgAV onset was spontaneous in 8 patients (18.2%), while potential triggers included upper respiratory infections (URTI) (23, 52.3%), gastroenteritis (5, 11.4%), lymphadenitis or trauma (3 each, 6.8%), and skin infection or preseptal cellulitis (1 each, 2.3%). The hBD-2 levels of patients with IgAV (median:10410 pg/dl);min-max: 6410-55614 pg/dl) were higher than in healthy controls (median:8662 pg/dl; min-max: 5438-18303 pg/dl) ($p=0.005$). Among IgAV patients, hBD-2 levels were higher in patients who were 10 years or older ($p=0.008$). Additionally, hBD-2 levels were higher in patients with a history of URTI prior to the onset of the disease compared to those with spontaneous IgAV ($p=0.015$).

Conclusion: Patients with IgAV had higher blood hBD-2 levels than healthy controls. Furthermore hBD-2 levels in IgAV patients who are older than 10 years were higher. That age difference was not observed in the healthy control group. Despite the control group had a higher median age and patients who are older had higher hBD-2 levels, it's outstanding that we have found hBD-2 levels higher in IgAV group than the healthy control group. Additionally, patients who suffered from URTI had higher hBD-2 levels than the spontaneous group. Despite URTI is the most common predisposing factor in our study group, it only covered half of the cases. These results indicate that elevation of hBD-2 levels in IgAV patients doesn't necessarily correlate with age or infection alone, and it may serve as a marker for the disease.

Disclosure

None declared

References

- Oni L, Sampath S. Childhood IgA Vasculitis (Henoch Schonlein Purpura)- Advances and Knowledge Gaps. *Front Pediatr*. 2019 Jun 27;7:257. doi: <https://doi.org/10.3389/fped.2019.00257>. ū2. Harder J. et al. A peptide antibiotic from human skin. *Nature* 1997;387:861-3. O'Neil DA. Regulation of expression of beta-defensins: endogenous enteric peptide antibiotics. *Mol Immunol*. 2003 Nov;40(7):445-50. doi: [https://doi.org/10.1016/s0161-5890\(03\)00161-4](https://doi.org/10.1016/s0161-5890(03)00161-4).
- Dalcin D et al. The Role of Human Beta-Defensin-2 in Pseudomonas aeruginosa Pulmonary Infection in Cystic Fibrosis Patients. *Infect Dis Ther*. 2013 Dec;2(2):159-66. doi: <https://doi.org/10.1007/s40121-013-0015-5>.

P121

JIA T cells use cysteine instead of cystin porters to produce glutathione and control ferroptosis at the site of inflammation

C. Neullens¹, S. H. Subramanyam¹, J. V. Loosdregt², B. Vastert², K. Ohl², K. Tenbrock¹

¹Translational Pediatric Rheumatology, RWTH Aachen, Aachen, Germany, ²UMC, Utrecht, Netherlands, ³Immunology, RWTH Aachen, Aachen, Germany

Correspondence: K. Tenbrock *Pediatric Rheumatology*, **23(2)**: P121

Introduction: Ferroptosis has been identified as a type of regulated cell death that is driven by lipid peroxidation. Cells have evolved various defense mechanisms to detoxify these toxic lipid peroxides. Especially T cells established a fine-tuned redox-balance as reactive oxygen species (ROS) are required to activate T cells, while too high amounts are deleterious for their function. We had shown that T cells in inflamed tissue have significantly enhanced mitochondrial ROS and

therefore in need of antioxidant defense and dependent on mechanism to counteract ferroptosis.

Objectives: The aim of this work was to clarify the role of ferroptosis in JIA.

Methods: We analyzed CD4+ T cells from peripheral blood and from inflamed joints of these patients.

Ferroptosis-associated genes and proteins in CD4 T cells were analyzed by qRT-PCR and flow cytometry. Lipid peroxidation was induced in CD4 T cells by sulfasalazine and erastin and subsequent functional analysis was performed by *in vitro* assays. Synovial fluid and PBMC T cells from JIA patients were analyzed by flow cytometry

Results: The suppression of the extrinsic NRF2/SLC7A11 pathway induced lipid peroxidation in T cells. Induction of ferroptosis by sulfasalazine and erastin reduced inflammatory cytokine production in control T cells while not in JIA T cells. JIA T cells exhibited reduced NRF2 and SLC7A11 expression as well as reduced CD36 expression, which is the main transporter of lipid peroxides in tumor associated T cells, which undergo enhanced ferroptosis. Instead of SLC7A11 the Cysteine transporter ASCT1 is upregulated in synovial fluid T cells and blockade of this transporter reduces IFN γ production.

Conclusion: Synovial fluid JIA T cells upregulate ASCT1 to import Cysteine and to compensate for negligible SLC7A11 expression and thus Cysteine-import. Both can substitute for the production of Glutathione, which is the major antioxidative molecule. We thus identified a novel pathway in inflammatory T cells that prevents ferroptosis and cell death. Blocking Cysteine import might be a novel therapeutic opportunity in JIA.

Disclosure

None declared

P122

Precision therapy for rare pediatric immune-mediated diseases: development of a peptide-based biosensor system to detect aberrant jaks kinase activity

R. Franca¹, L. Pugnetti³, N. Parmesan², A. Muzzo¹, P. Rispoli¹, S. Braidotti⁴, A. Tommasini^{1,4}, S. Pastore⁴, M. Zajc Avramovic^{5,6}, B. Jenko Bizjan^{5,6}, A. Taddio^{1,4}, T. Avcin^{5,6}, G. Stocco^{1,3}

¹Department of Medical, Surgical and Health Sciences, ²PhD School in Personalized Medicine and Innovative Therapies, University of Trieste, ³Department of Advanced Translational Diagnostics, ⁴Department of Pediatrics, Institute for Maternal & Child Health (I.R.C.C.S) Burlo Garofolo, Trieste, Italy, ⁵Department of Pediatrics, University of Ljubljana, ⁶Department of Allergology, Rheumatology and Clinical Immunology, University Children's Hospital, University Medical Center Ljubljana, LJUBLJANA, Slovenia

Correspondence: R. Franca

Pediatric Rheumatology, **23(2)**: P122

Introduction: The recent development of tyrosin kinase JAK inhibitors (JAKi) has brought an important change in the treatment of multiple immune-mediated disorders.

Objectives: The aim of the study is to develop a peptide-based biosensor system to detect aberrant JAK activity in primary cells from pediatric patients affected by these diseases among those enrolled in the INTERREG VI-A Italy - Slovenia "CONCERTO" project, and to screen *in vitro* and *a priori* the efficacy of JAK inhibitors (JAKi), providing integrative information to current diagnosis and monitoring of JAK-related diseases.

Methods: The biosensors, P_{JAK2-S} and P_{JAK2-L}, are biotinylated peptide probes with sequences that include a tyrosine (Y) phosphorylation site specific for JAK2. Initial analysis was conducted on HEL and SET2 immortalized cell lines, which harbor the JAK2 V617F gain-of-function mutation. Activation/phosphorylation of JAK2 in whole cell lysates and immunoprecipitated full-length JAK2 was analyzed in Western Blot. JAK2-mediated phosphorylation of biosensors was indirectly measured using a luminescent ADP detection kit, or directly assessed via fluorescence using a solid-phase ELISA assay with an anti phospho-Y primary antibody.

Results: We first provide evidence that P_{JAK2-S} and P_{JAK2-L} were suitable substrate sequences of JAK2 catalytic domain (JAK2-JH1). ADP was released when 2.5 ng/μl JAK2-JH1 was incubated with the peptide biosensors, achieving statistical significance for P_{JAK2-S} at 10 μM

and P_{JAK2-L} at 20 μ M (RLU basal phosphorylation of JAK2-JH1 *versus* 10 μ M P_{JAK2-S} or 20 μ M P_{JAK2-L} phosphorylation = median \pm SEM = 21.0 \pm 3.0 *versus* 190.3 \pm 44.75 or 182.5 \pm 18.06, respectively, both $p < 0.05$, two-way ANOVA, Bonferroni post-test). Notably, an increased in ADP detection could not be observed in the presence of $P_{PHOSPHO-JAK2-L}$, a phosphorylated form of P_{JAK2-L} or with peptide probes specific for the ABL kinase. In the ELISA assay, the phosphorylation P_{JAK2-L} and P_{JAK2-S} could not be detected above the baseline level of whole cell lysates. Several efforts were made in the lysates-biosensors incubation step to optimize the ELISA results, including changes in lysate amount (4 μ g *versus* 40 μ g), stringency of lysis buffer (TKB *versus* RIPA), time (1h *versus* 2h) and temperature (25°C *versus* 37°C). P_{JAK2-L} and P_{JAK2-S} were exposed to full length JAK2, isolated from the whole cell lysates by immunoprecipitation. However, they were not phosphorylated above background levels in any experimental condition tested, despite the presence of active/phosphorylated JAK2 confirmed by Western Blot. Significantly higher fluorescence values than baseline were observed for $P_{PHOSPHO-JAK2}$, used as technical positive control for the ELISA assay ($P < 0.0001$, Two-way ANOVA, Bonferroni's post-test).

Conclusion: P_{JAK2-S} and P_{JAK2-L} are suitable peptide sequences for monitoring the activity of JAK2-JH1 although further optimization is needed for their use with full-length JAK2.

Trial registration identifying number: This work was carried out with the contribution of the project 'CONCERTO'; CUP C93C22009370005, funded by the INTERREG VI-A Italy - Slovenia Programme 2021-2027

Disclosure

None declared

P125

Timed squat test as a functional outcome measure in childhood idiopathic inflammatory myopathies: correlation with CMAS, MMT8, and DAS

A. Alkandari¹, C. K. Lam¹, K. Peralta¹, Y. Goh^{1,2}, K. Chiu^{1,3}, J.-A. Marcuz³, K. Whitney^{1,3}, B. M. Feldman^{1,4,5}

¹Division of Rheumatology, The Hospital for Sick Children, ²SickKids Research Institute, Child Health Evaluative Sciences, ³Department of Rehabilitation, The Hospital for Sick Children, ⁴Department of Paediatrics, Faculty of Medicine, University of Toronto, ⁵Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada

Correspondence: A. Alkandari

Pediatric Rheumatology,

23(2): P125

Introduction: Monitoring muscle strength and function in children with idiopathic inflammatory myopathies (IIM) is essential for effective disease management. While established tools such as the Childhood Myositis Assessment Scale (CMAS), Manual Muscle Testing (MMT-8), and Disease Activity Score (DAS) are widely used, functional performance measures like the timed squat test (TST) may offer practical, real-time insights into clinical status. This study evaluates the utility of the TST by comparing its results with CMAS, MMT-8, and DAS in children with IIM.

Objectives: To assess the potential of timed squat counts as a functional outcome measure in routine assessments of children with IIM, in relation to CMAS, MMT-8, and DAS.

Methods: A retrospective review was conducted on children with IIM at a tertiary center between June 1, 2018, and December 31, 2023. Generalized estimating equations (GEE) were used to model squat performance against CMAS, MMT-8, and DAS across all clinical visits. Additional analyses included baseline correlation matrices, standardized response mean (SRM) calculations in a 21-patient inception cohort (baseline to 6 months), and visualization of repeated measures using jittered scatter plots with LOESS curves.

Results: Eighty children with IIM were identified; six were excluded due to missing or non-applicable data. The final cohort included 66 with juvenile dermatomyositis (JDM), five with amyopathic JDM, two with overlap myositis, and one with necrotizing myopathy. The mean age at disease onset was 8.49 years, and 74% were female. Most (81%) were classified as having definite IIM, and 19% as probable. GEE modeling showed a significant positive association between squat counts and CMAS (estimate = 0.39, $p = 0.031$) and MMT-8 (estimate = 0.1, p

= 0.004), and a significant negative association with DAS (estimate = -0.89, $p < 0.001$). Correlation matrices at baseline supported these findings. SRM analysis demonstrated TST responsiveness to clinical change over 6 months. Scatter plots showed consistent trends across visits: higher CMAS and MMT-8 scores correlated with better TST performance, while higher DAS scores were associated with reduced performance. The TST showed a floor effect in weaker patients but avoided the ceiling effect seen in CMAS and MMT-8 as strength improved.

Conclusion: The TST correlates significantly with CMAS, MMT-8, and DAS and is responsive to clinical change. Its simplicity and real-time applicability make it a useful tool for routine clinical monitoring in pediatric IIM.

Disclosure

None declared

P126

Clinical characteristics and prognostic factor in juvenile dermatomyositis: data of the spanish registry

C. Esquirol-Herrero¹, S. Carriquí-Arenas¹, J. M. Mosquera¹, E. Quesada-Masachs², M. López², D. Clemente³, A. Boteanu⁴, C. Udaondo⁵, J. de Inocencio⁶, J. C. Nieto⁷, L. Riancho⁸, E. Núñez⁹, J. Sánchez-Manubens¹, M. J. Lirola¹⁰, R. Roldán¹¹, M. Camacho¹², M. Martínez¹³, M. Medrano¹⁴, P. Alcañiz¹⁵, J. Antón¹, E. Iglesias¹

¹Pediatric Rheumatology, Hospital Sant Joan de Déu, ²Pediatric Rheumatology, Vall d'Hebron University Hospital, Barcelona, ³Pediatric Rheumatology, Niño Jesús Hospital, ⁴Rheumatology, Ramón y Cajal University Hospital, ⁵Pediatric Rheumatology, La Paz University Children's Hospital, ⁶Pediatric Rheumatology, University Hospital 12 de octubre, ⁷Rheumatology, Gregorio Marañón General University Hospital, Madrid, ⁸Rheumatology, Valdecilla Hospital, Santander, ⁹Pediatric Rheumatology, Regional University Hospital of Malaga, Málaga, ¹⁰Pediatrics, Instituto Hispalense de Pediatría, Sevilla, ¹¹Pediatric Rheumatology, University Hospital Reina Sofía, Córdoba, ¹²Pediatric Rheumatology, Virgen del Rocío University Hospital, Sevilla, ¹³Rheumatology, Germans Trias i Pujol University Hospital, Badalona, ¹⁴Rheumatology, Miguel Servet University Hospital, Zaragoza, ¹⁵Pediatric Rheumatology, Virgen de la Arrixaca University Clinical Hospital, Murcia, Spain

Correspondence: C. Esquirol-Herrero *Pediatric Rheumatology*, **23(2):** P126


Introduction: Juvenile Dermatomyositis (JDM) is the most common chronic idiopathic inflammatory myopathy in children. The diagnosis is clinical. Baseline laboratory and complementary studies trace the phenotype of these patients.

Objectives: The objective of this study was to describe epidemiological, clinical and laboratory characteristics at diagnosis of JDM patients included in the Spanish JDM registry, as well as to identify prognostic factors on these patients.

Methods: Retrospective review of clinical features, laboratory tests, and complementary studies at diagnosis of JDM patients included on the Spanish JDM registry. These data were analyzed to assess whether there was a relationship with the development of complications and time to disease inactivity.

Results: One hundred and sixteen patients from 17 Spanish paediatric rheumatology centres were included, 76 girls (65%). Median age at diagnosis was 7.3 years (Interquartile range (IQR) 4.5–10.2). All patients had pathognomonic skin lesions at the beginning of the disease. Muscle weakness was present in 86.2%. Median Childhood Muscle Assessment Scale was 34 (IQR 22–47). Twelve patients (34%) had dysphagia and 3.5% dysphonia. Anti-p155 was the most frequently detected myositis specific antibody, followed by anti-MDAS. Twenty-nine patients developed calcinosis and 4 presented with macrophage activation syndrome. 70% reached inactivity in a median time of 8.9 months (IQR 4.5–34.8). 41% relapsed after a median time of 14.4 months (IQR 8.6–22.8) of inactivity. Shorter time to treatment was associated with better prognosis (Hazard ratio (HR) = 0.95 per month of evolution, $p = 0.02$). Heliotrope rash at diagnosis correlates with higher risk of development complications.

Conclusion: We describe heliotrope rash as a risk factor for developing complications in our cohort of JDM patients, an easy-to-evaluate



**SOCIETÀ ITALIANA
DI FARMACOLOGIA**



XXVI Conference of

**YOUNG SIF
PHARMACOLOGISTS**

November 30th – December 2nd, 2025

Bologna - Italy

Program

EXECUTIVE COUNCIL

President

Armando Genazzani

President Elect

Monica DiLuca

Councillors

**Mariarosaria Bucci
Vincenzo Calderone
Carmela Fimognari
Ferdinando Nicoletti
Marco Pistis
Patrizia Popoli**

Secretary

Fabrizio Gardoni

Past President

Giuseppe Cirino

Scientific Committee

**Maria Antonietta Barbieri
Valerio Ciccone
Silvana Gaetani
Fabrizio Gardoni
Armando Genazzani
Elena Lucarini
Arianna Pani
Maria Antonietta Riemma**

Conference Presentation

In a time of rapid and transformative advances across all scientific disciplines — from biotechnology and artificial intelligence to personalized medicine and digital health — **pharmacology stands at the heart of innovation in biomedical research.** The development of safer, more effective and more accessible therapies is increasingly driven by interdisciplinary collaboration, advanced technologies and a renewed understanding of human physiology and disease.

In this evolving landscape, **young pharmacologists play a pivotal role.** Their natural curiosity, openness to innovation and capacity for fast learning and adaptation make them uniquely equipped to embrace and shape the future of pharmacological science. Investing in their development means investing in the future of healthcare.

We are therefore delighted to welcome you to the 26th edition of the Conference of Young Pharmacologists, organized by the Italian Society of Pharmacology. The event will take place in Bologna from November 30th to December 2nd, 2025.

Our mission is to bring together a vibrant community of early-career pharmacologists, including postgraduate students, PhD candidates, postdoctoral fellows and young investigators from across the pharmacological sciences. The conference aims to foster scientific exchange, promote interdisciplinary collaboration and support the professional development of young researchers, both in academic and non- academic sectors.

This year's scientific program will highlight key research areas, including:

- **Cancer Pharmacology**
- **Cardiovascular and Metabolic**
- **Clinical Pharmacology**
- **Gender Pharmacology**
- **Immunology meets Pharmacology**
- **Inflammation**
- **Neurodegenerative Diseases**
- **Neuropharmacology and Addiction Disorders**
- **Neuropsychopharmacology**
- **Obesity, Metabolic Syndrome and Eating Disorders**
- **Pain Pharmacology**
- **Pharmacognosy, Phytotherapy and Nutraceuticals**
- **Pharmacology of Integrated Systems**
- **Pharmacovigilance, Pharmacoepidemiology, Pharmacoconomics & Real World Evidence**
- **Rare Diseases and Orphan Drugs**

Building on the success of previous editions, the 2025 conference will also introduce new and exciting opportunities:

- **Mentorship sessions**, offering direct dialogue between senior scientists and young pharmacologists
- **Industry scouting events**, connecting early-career researchers with companies involved in drug development, clinical trials, medical technologies and regulatory science
- **Live demonstrations of innovative research tools**, showcasing cutting-edge techniques, platforms and instrumentation at the forefront of pharmacological innovation

Participants will have the opportunity to present their research through oral and poster presentations, selected via peer-reviewed abstract submission. The program will also include plenary lectures, workshops on soft skills, career development sessions, networking opportunities and thematic roundtables.

Organized by the SIF Early Career Pharmacologists Group (SIF-ECPG), the event will welcome up to 200 attendees. To foster international participation, all sessions will be conducted in English.

We look forward to welcoming you in Bologna this November to be part of this inspiring event.

JOIN US AND HELP SHAPE THE FUTURE OF PHARMACOLOGY!

Maria Antonietta Barbieri
Valerio Ciccone
Elena Lucarini
Arianna Pani
Maria Antonietta Riemma
[SIF-ECPG Committee](#)

VENUE

**Best Western
Plus Tower Hotel Bologna**
Viale Lenin, 43
40138 Bologna



ORGANIZING AND SCIENTIFIC SECRETARIAT

**SIF - Società Italiana
di Farmacologia**
Via Giovanni Pascoli, 3
20129 Milano
segreteria@sifweb.org
www.sifweb.org



ORGANIZING SECRETARIAT

Planning Congressi srl
Via Guelfa, 9
40138 Bologna
+39 051 300100
www.planning.it



Ramona Cantelli
r.cantelli@planning.it

Sunday November 30th, 2025

13.00	Participants' Registration			
	SALA FELSINA 1-2			
14.00-15.00	Welcome remarks and opening ceremony			
15.00-16.00	Plenary Lecture Genetic Mutations and Biomarkers: Maximizing Drug Effectiveness in Oncology Romano Danesi			
16.00-16.30	<i>Coffee Break</i>			
	SALA MAGGIORE	SALA ARTEMISI	SALA FELSINA 1-2	SALA FOYER
16.30-18.30	Session 1 Obesity, Metabolic Syndrome and Eating Disorders	Session 2 Pharmacovigilance, Pharmacoepidemiology, Pharmacoeconomics & Real World Evidence	Session 3 Neuropsychopharmacology I	Session 4 Cancer Pharmacology I
18.30-20.00	Poster Session 1 Poster Area Garisenda - Riccadonna			
20.30	<i>Welcome Cocktail</i>			

Monday December 1st, 2025

	SALA MAGGIORE	SALA ARTEMISI	SALA FELSINA 1-2	SALA FOYER
9.00-11.00	Session 5 Pain Pharmacology	Session 6 Immunology meets Pharmacology (Joint Session with SIICA and EFIS)	Session 7 Cardiovascular and Metabolic	Session 8 Neuropsychopharmacology II
11.00-11.30	<i>Coffee break</i>			
	SALA FELSINA 1-2			
11.30-12.15	Workshop Principles and Critical Issues in the Preclinical and Clinical Evaluation Process of New Drugs Patrizia Popoli			
12:15-13:00	Workshop Basic Principles of Technology Transfer: Possible Applications in Drug Development Filippo Caraci			
13.30-15.00	<i>Lunch</i>			
	SALA FELSINA 1-2			
15.00-15.30	Workshop Farindustria Pharmaceutical Industry Careers: What Young Pharmacologists Need to Know Marco Zibellini			
15.30-16.30	Workshop SiMeF From Passion to Profession: Careers in Pharmaceutical Medicine Marisa Le Donne, Mario Spione In collaborazione con Mario Mangrella, Luca Miglierina, Simona Paratore			
16.30-17.00	<i>Coffee break</i>			
	SALA MAGGIORE	SALA ARTEMISI	SALA FELSINA 1-2	SALA FOYER
17.00-19.00	Session 9 Pharmacognosy, Phytotherapy and Nutraceuticals	Session 11 Pharmacology of Integrated Systems	Session 12 Cancer Pharmacology II	Session 13 Neuropharmacology and Addiction Disorders
	Session 10 Rare Diseases and Orphan Drugs			
19.00-20.30	Poster Session 2 Poster Area Garisenda-Riccadonna			
21.00	<i>Dinner</i>			

Tuesday December 2nd, 2025

	SALA MAGGIORE	SALA ARTEMISI	SALA FELSINA 1-2	SALA FOYER
9.00-11.00	Session 14 Neurodegenerative Diseases	Session 15 Gender Pharmacology	Session 16 Clinical Pharmacology	Session 17 Inflammation
11.00-11.30	<i>Coffee break</i>			
	SALA FELSINA 1-2			
11.30-12.15	Plenary Lecture SMIT1 as a novel therapeutic target in cardiometabolic HFpEF Alice Marino			
12:15-13:00	Closing Ceremony			

Sunday November 30th, 2025

Sala Felsina 1-2

- 14.00-15.00 **Welcome remarks and opening ceremony**
Armando Genazzani (Turin), Silvana Gaetani (Rome), Maria Antonietta Riemma (Naples)
- 15.00-16.00 **Plenary Lecture**
Chairpersons: Armando Genazzani (Turin), Arianna Pani (Milan)
Genetic Mutations and Biomarkers: Maximizing Drug Effectiveness in Oncology
Romano Danesi (Milan)

Sala Maggiore

Oral Communication Session 1

Obesity, Metabolic Syndrome and Eating Disorders

Chairpersons: Federica Comella (Naples), Barbara Eramo (Rome)

- 16.30-16.45 **The natural sulfur compounds Erucin and Sulforaphane promote antioxidant effects and modulate the de-novo browning process on 3T3-L1 preadipocyte cells**
Flori Lorenzo (Pisa), Galgani Giulia, Bray Giorgia, Ippolito Chiara, Segnani Cristina, Pagnotta Eleonora, Ugolini Luisa, Citi Valentina, Pellegrini Carolina, Nieri Paola, Bernardini Nunzia, Martelli Alma, Vincenzo Calderone
- 16.45-17.00 **OEA Reverses Metabolic and Structural Alterations in Skeletal Muscle Induced by High-Fat Diet**
Sepe Christian (Rome), Campagna Alessia, Friuli Marzia, Eramo Barbara, Vari Francesco, Vergara Daniele, Giudetti Anna Maria, Romano Adele, Gaetani Silvana
- 17.00-17.15 **Role of the histone deacetylase inhibitor MS-275 on maladaptive feeding behaviour in a rat model of binge eating**
Einaudi Giacomo (Camerino), Botticelli Luca, Micioni Di Bonaventura Emanuela, Koziara Zuzanna, Pucci Mariangela, D'Addario Claudio, Mammoli Valerio, Mai Antonello, Zwergel Clemens, Conte Elena, Coppi Lara, Crestani Maurizio, Cifani Carlo, Micioni Di Bonaventura Maria Vittoria

- 17.15-17.30 **MS-275 HDAC inhibitor as a therapeutic modulator of skeletal muscle alterations in a rat model of Binge Eating behavior**
Dinoi Giorgia (Bari), Rubino Egidio Maria, Mai Antonello, Lanza Martina, Crestani Maurizio, Cifani Carlo, De Luca Annamaria, Imbrici Paola, Liantonio Antonella, Micioni Di Bonaventura Maria Vittoria, Conte Elena
- 17.30-17.45 **Investigation of the effect of a selective dopamine D4 receptor (D4R) antagonist in an animal model of binge eating**
Botticelli Luca (Camerino), Einaudi Giacomo, Koziara Zuzanna, Micioni Di Bonaventura Emanuela, Del Bello Fabio, Mammoli Valerio, Provensi Gustavo, Costa Alessia, Matteucci Federica, Quaglia Wilma, Piergentili Alessandro, Giorgioni Gianfabio, Micioni Di Bonaventura Maria Vittoria, Cifani Carlo
- 17.45-18.00 **Clozapine-induced myotoxicity**
Buffi Gloria (Urbino), Fiorani Mara, Guidarelli Andrea, Spina Andrea, Scocchia Lorenzo, Renna Giorgia Maria, Zito Ester, Cantoni Orazio
- 18.00-18.15 **Peripheral and central dysregulation of the immune system in the Activity-Based Anorexia model**
Parolaro Susanna (Milan), Mottarlini Francesca, Da Dalt Lorenzo, Baragetti Andrea, Rizzi Beatrice, Bonacina Fabrizia, Norata Giuseppe Danilo, Fumagalli Fabio, Caffino Lucia

Sala Artemisi

Oral Communication Session 2

**Pharmacovigilance, Pharmacoepidemiology,
Pharmacoeconomics & Real World Evidence**

Chairpersons: Maria Antonietta Barbieri (Messina), Giulia Valdiserra (Pisa)

- 16.30-16.43 **Uncovering Prognostic Biomarkers Through a Pharmacovigilance study: The Case of RDW**
Liguori Valerio (Naples), Anatriello Antonietta, Zinzi Alessia, Ragone Angela, Pentella Ciro, Capuano Annalisa, Rafaniello Concetta, Naviglio Silvio, Sapio Luigi
- 16.43-16.56 **Spatio-Temporal Epidemiology of Mental Health Crisis Care in Countries with Temperate Climates: Towards a National Health Emergency Access Index**
Eloho B. Obukohwo (Sweden)
- 16.56-17.09 **Randomized clinical trial replication and second-stage study to evaluate the risk of serious infections in biological drug users with psoriatic arthritis or psoriasis using the Italian VALORE distributed database network**
Spini Andrea (Verona), L'Abbate Luca, Ingrasciotta Ylenia, Carollo Massimo, Soardo Federica, Bellitto Chiara, Pellegrini Giorgia, Leoni Olivia, Zanforlini Martina, Ancona Domenica, Stella Paolo, Cavazzana Anna, Scapin Angela, Lopes Sara, Belleudi Valeria, Ledda Stefano, Carta Paolo, Rossi Paola, Ejlli Lucian, Sapigni Ester
- 17.09-17.22 **Evaluation of the safety profile of glucagon-like peptide-1 receptor agonists: a focus on thyroid cancer-related adverse events by using the European Pharmacovigilance database**
Anatriello Antonietta (Naples), Liguori Valerio, Pentella Ciro, Laino Ludovica Vittoria, Sullo Maria Giuseppa, Sportiello Liberata, Mascolo Annamaria, Scavone Cristina, Capuano Annalisa
- 17.22-17.35 **Safety Profile of Zavegepant in the Treatment of Migraine: Preliminary Insights from the FAERS Database**
Cicala Giuseppe (Messina), Barbieri Maria Antonietta, Russo Giulia, Spina Edoardo

17.35-17.48

Determinants of lipid-lowering therapy initiation and long-term outcomes post-hospitalization for an atherosclerotic cardiovascular event: a retrospective cohort study using Lombardy administrative databases

Scotti Stefano (Milan), Olmastroni Elena, Galimberti Federica, Bruno Giacomo Matteo, Colombo Giorgio Lorenzo, Alieva Asiat, Xie Sining, Catapano Alberico Luigi, Casula Manuela

17.48-18.01

Cardiovascular Safety Profile of BRAF and MEK Inhibitors in Melanoma: FAERS Data Through a Retrospective Disproportionality Analysis

Russo Giulia (Messina), Barbieri Maria Antonietta, Cicala Giuseppe, Zito Concetta, Silvestris Nicola, Santarpia Mariacarmela, Spina Edoardo

18.01-18.14

Adherence and safety of bulevirtide in chronic hepatitis delta: real-world experience from a pharmacist-led patient education program

Cadore Alessandro (Padua), Mengato Daniele, Giunco Elisabetta Mariavittoria, Zanaga Paola, Zappitelli Teresa, Romano Antonietta, Tonon Marta, Pasin Francesca, Barbaro Francesco, Sasset Lolita, Scribano Laura, Gambato Martina, Battistella Sara, Simioni Paolo, Cattelan Annamaria, Burra Patrizia, Ferri Nicola, Venturini Francesca, Russo Francesco Paolo

18.14-18.27

Efficacy and safety of drugs for transthyretin amyloidosis: a systematic review with meta-analysis

Veneziano Sara (Pisa), Piragine Eugenia, Martelli Alma, Calderone Vincenzo

Sala Felsina 1-2

Oral Communication Session 3

Neuropsychopharmacology I

Chairpersons: Barbara Fülöp (Hungary), Elena Lucarini (Florence)

- 16.30-16.45 **GluA3-containing AMPA receptors in health and disease: from synapses to circuits and behaviour**
Italia Maria (Milan), Spinola Alessio, Zianni Elisa, Caruso Sofia, Gomez Blanco José Ignacio, Pelucchi Silvia, Marcello Elena, DiLuca Monica, Gardoni Fabrizio
- 16.45-17.00 **Altered tryptophan metabolism and dopaminergic disinhibition following prenatal cannabis exposure**
Leone Roberta (Cagliari), Carli Marco, Coraddu Camilla, Melis Miriam
- 17.00-17.15 **Investigating miR-484 and miR-18a-3p role in ketamine-induced vomiting and recovery agitation**
Messineo Luca (Trieste), Frau Roberto, De Gennaro Alessia, Concas Luca, Cozzi Giorgio, Barbi Egidio, D'Adamo Pio, Stocco Gabriele, Lucafò Marianna
- 17.15-17.30 **Impact of prenatal enhancement of endocannabinoid signaling on dopaminergic circuitry development through Netrin-1/DCC system**
Carli Marco (Cagliari), Coraddu Camilla, Serra Valeria, Melis Miriam
- 17.30-17.45 **Perinatal fluoxetine exposure disrupts sensitive periods dynamics: sex-specific molecular and behavioral effects**
Gallo Maria Teresa (Milan), Virenque Anais, Golinelli Alessia, Fumagalli Fabio, Castrén Eero, Brivio Paola, Calabrese Francesca
- 17.45-18.00 **Prenatal Stress Exposure Induce Behavioral Alterations and Transcriptomic Changes in the Peripheral Blood and Ventral Hippocampus of Pregnant Dams**
Zonca Valentina (Milan), Begni Veronica, Riva Marco Andrea, Cattaneo Annamaria
- 18.00-18.15 **Central and Peripheral Inflammation as Key Mechanisms of Vulnerability in Adult Rats Exposed to Prenatal Stress**
Petrillo Giulia (Milan), D'Aprile Ilari, Zonca Valentina, Mazzelli Monica, Riva Marco Andrea, Cattaneo Annamaria

- 18.15-18.30 **Unraveling the Role of Oxytocin in the Lasting Impact of Early-Life Attachment Disruption**
Mancini Camilla (Camerino), Nutarelli Sofia, Massa Greta, Passeri Alice, Babicola Lucy, Di Segni Matteo, Canterini Sonia, Viscomi Maria Teresa, Cifani Carlo, Ventura Rossella

Sala Foyer

Oral Communication Session 4

Cancer Pharmacology I

Chairpersons: Valerio Ciccone (Siena), Mirco Masi (Genoa)

- 16.30-16.45 **Extracellular Nicotinamide Phosphoribosyltransferase (eNAMPT) Shapes Pericytes Promoting Breast Cancer Progression**
Moro Marianna (Novara), Balestrero Federica Carolina, Genazzani Armando, Grolla Ambra
- 16.45-17.00 **Characterizing eNAMPT-Mediated Circulating Tumour Cells Modulation During Breast Cancer Progression**
Balestrero Federica Carolina (Novara), Moro Marianna, Clemente Nausicaa, Petrikaite Vilma, Genazzani Armando, Grolla Ambra
- 17.00-17.15 **Mic60 loss in breast cancer induces epithelial-mesenchymal transition (EMT) phenotype**
Esposito Camilla (Naples), Perego Michela, Altieri Dario, Panza Elisabetta, Cirino Giuseppe
- 17.15-17.30 **Targeting Neurotransmitter Receptors in combination with Metronomic Chemotherapy: A Novel Therapeutic Strategy for Brain Metastases in Breast Cancer**
Bandini Arianna (Pisa), Orlandi Paola, Banchi Marta, Bocci Guido
- 17.30-17.45 **BMP-1 Inhibition Modulates Tumor Growth and Cytokine Responses in Combination with Doxorubicin in a Mouse Model of Metastatic Breast Cancer**
Bayram Talay Deniz (Turkey), Ferda Altaytaş, Esra Tavşan, Nuray Acar, Nuray Erin

- 17.45-18.00 **Challenging triple negative breast cancer through HDAC6 selective inhibition in cellular and organoid models**
Bello Ivana (Naples), Barone Simona, Esposito Camilla, D'Ariano Morena, Summa Vincenzo, Cirino Giuseppe, Brindisi Margherita, Panza Elisabetta
- 18.00-18.15 **Impact of drug-drug interactions on effectiveness and toxicity profile in patients treated with osimertinib with EGFR-positive non small cell lung cancer**
Perrotta Nicola (Rome), Fiorito Luigi Angelo, Gentile Rossella, Vescovo Roberta
- 18.15-18.30 **Preclinical evaluations of combination of chemotherapy and target-therapy in mucoepidermoid cancer cells**
Abate Andrea (Brescia), Bonera Claudia, Tamburello Mariangela, Marinoni Luisa, Bonini Sara Anna, Sigala Sandra

18.30-20.00

Poster Session 1 - Poster Area Garisenda – Riccadonna

Chiarpersons: Maria Antonietta Barbieri (Messina), Mariarosaria Bucci (Naples), Silvana Gaetani (Rome), Fabrizio Gardoni (Milan), Gianluca Gazzaniga (Rome), Carla Ghelardini (Florence), Arianna Pani (Milan), Maria Antonietta Riemma (Naples), Martina Smimmo (Naples), Andrea Spini (Verona)

P1/1

Alterations of the central oxytocinergic system in a mouse model of anorexia: implications for olfactory processing and immune signaling

Eramo Barbara (Rome), Xu Jingjing, Gaetani Silvana, Nilsson Ida AK, Romano Adele

P1/2

Antiseizure medication and direct oral anticoagulants: where are we?

Cancellerini Chiara, Caravelli Alice (Bologna), Esposito Roberta, Vignatelli Luca, Mostacci Barbara, Licchetta Laura, Bisulli Francesca

P1/3

Are We Hitting The Target? PK/PD Target Attainment with Continuous Infusion of Piperacillin-Tazobactam in Febrile Neutropenia

Russiani Francesco (Udine), Angelini Jacopo, Ferin Sara, Lo Re Francesco, Giuliano Simone, Flammini Sarah, Tascini Carlo, Stocco Gabriele, Baraldo Massimo

P1/4

Branched-chain amino acids supplementation as a strategy against sarcopenia: insights from *in vitro* assessments in muscle precursors from aged human

Ladisa Alberto (Bari), Mantuano Paola, Conte Elena, Bianchini Gianluca, Boccanegra Brigida, Lenti Roberta, Cappellari Ornella, Liantonio Antonella, Allegretti Marcello, Aramini Andrea, De Luca Annamaria

P1/5

Cannabinoids targeting inflammasome activation and programmed cell death in an *in vitro* model of neuroinflammation

Cullotta Chiara (Messina), Irrera Natasha, Bitto Alessandra

P1/6

Characterization of the toxic effects of the marine toxin ovatoxin-a on human skin keratinocytes

D'Arelli Alessandra (Trieste), Pelin Marco, Sosa Silvio, Tubaro Aurelia

P1/7

Disruption of PI3K/Akt/mTOR Signaling by PFOS in Differentiated Human Neurons: A miRNA-Mediated Mechanism

Ghelli Luca (Bologna), Graziosi Agnese, Sita Giulia, Hrelia Patrizia, Angelini Sabrina, Morroni Fabiana

P1/8

Exploring phenotypical differences in paediatric immortalised dystrophic cell lines: shifting toward personalized pharmacological therapies

Cristiano Enrica (Bari), Marinelli Manuel, Quarta Raffaella, Boccanegra Brigida, Cerchiara Alessandro Giovanni, Ladisa Alberto, Barile Simona, Mouly Vincent, Lasorsa Massimo, Imbrici Paola, Cappellari Ornella, De Luca Annamaria

P1/9

Implications of Unmet Primary Endpoints in Pivotal Trials: A Comparative Review of EMA and FDA Regulatory Decisions

Perini Martina (Novara), Nicola Panzeri

P1/10

Validation of biomarkers of sarcopenia in IN-TEMPO clinical trial: a step towards healthy aging via multidomain interventions

Lenti Roberta (Bari), Mantuano Paola, Ladisa Alberto, Pace Claudio, Cimmarusti Maria Teresa, Pontrelli Paola, Gesualdo Loreto, Solfrizzi Vincenzo, De Luca Annamaria

P1/11

Evaluation of the protective effect of erucin as H₂S - donor in vascular cells exposed to hyperglycemic conditions: inhibition of ferroptosis and alteration of the transsulfuration pathway

Bray Giorgia (Pisa), Mantuano Paola, Ladisa Alberto, Pace Claudio, Cimmarusti Maria Teresa, Pontrelli Paola, Gesualdo Loreto, Solfrizzi Vincenzo, De Luca Annamaria

P1/12

Involvement of cAMP/CREB/CSE Axis in Dapagliflozin's protective effects on HFpEF-induced Multiorgan Failure

Persico Gennaro (Naples), Smimmo Martina, Casale Veronica, Riemma Maria Antonietta, De Angelis Antonella, Monti Maria Chiara, Morretta Elva, Vellecco Valentina, Bucci Mariarosaria

P1/13

Mechanistic insights into the vascular actions of calebin A: dual modulation of smooth muscle CaV1.2 and KCa1.1 channels

De Rosa Francesca (Siena), Faiola Rosa, Bacci Aurora, Fusi Fabio

P1/14

New insight into the cardiovascular toxicity of Norbormide, a Rattus-selective toxicant

Bichicchi Alessia (Siena), Durante Miriam, Bertelli Eugenio, Saponara Simona

P1/15

Phase 1 clinical trials for metabolic syndrome in Europe: analysis of trends, distribution and regulatory context

Grosdani Stefano (Milan), Bertolani Arianna, Scatigna Marco

P1/16

Taurisolo®, a polyphenolic extract from Aglianico cultivar grape, as an ally against the endothelial damage induced by Trimethylamine N-oxide (TMAO)

Benedetti Giada (Naples), Abate Federico, Roggia Michele, Caradonna Eugenio, Tenore Gian Carlo, Cosconati Sandro, Novellino Ettore, Stornaiuolo Mariano, Calderone Vincenzo, Martelli Alma

P1/17

Sex related Differences in Oxytocin System Alterations and Social Reward Responsiveness in a Rat Model of Gaming Disorder

Casile Antonino (Camerino), Bonaldo Brigitta, Fallaha Alice, Bettarelli Martina, Micioni Di Bonaventura Maria Vittoria, Gotti Stefano, Cifani Carlo

P1/18

Bipolar disorder: biological aging and genome-wide methylation biomarkers

Meloni Anna (Cagliari), Pisanu Claudia, Minelli Alessandra, Congiu Donatella, Paribello Pasquale, Pinna Marco, Contu Martina, Buson Lisa, Chillotti Caterina, Bortolomasi Marco, Ardaù Raffaella, Gennarelli Massimo, Severino Giovanni, Del Zompo Maria, Manchia Mirko, Squassina Alessio

P1/19

Influence of CYP2B6 Gene Polymorphisms on Methadone Plasma Levels: An Analysis of Clinical Studies in Caucasian Population

Tamburrino Carmela (Naples), Donnarumma Danilo, Petrella Raffaella, Severino Alessandra Santina, Conti Valeria, Campobasso Carlo Pietro, Carfora Anna

P1/20

Integrated Pharmacokinetic–Pharmacogenomic framework for personalized Elexacaftor/Tezacaftor/Ivacaftor dosing in Cystic Fibrosis: design of a Regional Reference Hub ProgrammePerrotta Nicola (Rome)

P1/21

The role of clinical pharmacologist in optimizing the antiplatelet therapy considering pharmacogenetics and drug-drug interactionsZarella Adele (Salerno), Donnarumma Danilo, Petrella Raffaella, Severino Alessandra Santina, Conti Valeria, Campobasso Carlo Pietro, Carfora Anna

P1/22

TYMS genetic variants as possible predictive biomarkers of response to fluoropyridine treatment: the experience of the Pharmacogenetics Unit of University Hospital of SalernoMazza Ines (Salerno), De Bellis Emanuela, Donnarumma Danilo, De Stefano Alessandra, Valentino Dominga, Charlier Bruno, Campana Federica, Sabbatino Francesco, Pepe Stefano, Filippelli Amelia, Conti Valeria

P1/23

Anti-hyperalgesic effects of *Barbarea verna* extract and its glucosinolate derivatives in female rats with post-inflammatory visceral painTrisolini Samuele (Florence), Lucarini Elena, Micheli Laura, Ciampi Clara, Toti Alessandra, Margiotta Francesco, Cataldi Maria Giovanna, Pagnotta Eleonora, Righetti Laura, Di Cesare Mannelli Lorenzo, Ghelardini Carla

P1/24

Development of a mouse model of opioid-induced hyperalgesia: investigating the role of neuroinflammationMarcolin Emma (Padua), Barzon Benedetta, Nasini Sofia, Bardi Lucrezia, Comai Stefano, Zusso Morena

P1/25

Exploring the Role of Ladarixin in Diabetic Neuropathy and Retinopathy through CXCR1/2 InhibitionMorace Andrea Maria (Naples), Ricciardi Federica, Fusco Antimo, Perrone Michela, Di Martino Emanuele, Limongelli Rebecca, Bonsale Roozbe, Pagano Salvatore, Teweldemedhin Milena Melake, Boccella Serena, Belardo Carmela, Brandolini Laura, Guida Francesca, Maione Sabatino, Luongo Livio

P1/26

Human iPSCs-derived dorsal root ganglia organoids: an innovative in vitro 3D model to investigate chemotherapy-induced peripheral neuropathyCataldi Maria Giovanna (Florence), Venturi Daniel, Toti Alessandra, Margiotta Francesco, Lucarini Elena, Curti Lorenzo, Polverini Federica, Masi Alessio, Cherchi Federica, Frulloni Lucia, Coppi Eisabetta, Carozzo Francesco, Mello Tommaso, Di Cesare Mannelli Lorenzo

P1/27

***In vitro* pharmacological investigation of novel NOP non peptide partial agonists**

Maritan Michele (Padua), Frezza Alessia, Pola Pietro, Ruzza Chiara, Malfacini Davide, Doshi Arpit, Yasuda Dennis, Zaveri Nurulain T, Calò Girolamo

P1/28

Looking for NOP receptor biased agonists: a SAR study on N/OFQ (1-13)-NH₂

Morrone Erika (Padua), Rizzo Alessandra, Marzola Erika, Meneguzzo Giulio, Malfacini Davide, Guerrini Remo, Calò Girolamo

P1/29

Potential role of the hydroxyl carboxylic acid receptor type 2 (HCAR2) in microglia pathophysiology and pain implications

Di Martino Emanuele (Naples), Ricciardi Federica, Perrone Michela, Belardo Carmela, Boccella Serena, Fusco Antimo, Morace Andrea Maria, Guida Francesca, Palazzo Enza, Maione Sabatino, Luongo Livio

P1/30

A Novel Preclinical Approach to Evaluate Early Interstitial Lung Disease: Efficacy of the Administration of a Nanostructured Prodrug of Mycophenolic Acid

Mantovani Elena (Novara), Ragnoli Beatrice, Clemente Nausicaa, Marengo Alessandro, Russo Davide, Ronchail Alessio, Malerba Mario, Chiazza Fausto

P1/31

Integrated molecular imaging, RT-qPCR, and functional approaches for investigating TGF- β 1 induced epithelial-mesenchymal transition in A549 Cells

Medjiofack Djeujo Francine (Padua), Negrini Marco Solimano, Ferri Pietro, Mion Andrea, Malfacini Davide, Ruscitti Francesca, Pitozzi Vanessa, Marchini Gessica, Trevisani Marcello, Calò Girolamo

P1/32

A New Era for Drug Repurposing: REMEDI4ALL's Vision and Platform

Passaro Eugenia (Naples), Leone Alessandra, Roca Maria Serena, Iannelli Federica, Migliorino Rossella, Barile Veronica, Vitagliano Carlo, Borrelli Marco, Foschini Francesca, Silvestro Lucrezia, Fratelli Maddalena, Fracasso Claudia, Lucchetti Jacopo, Gobbi Marco, Bruzzese Francesca, Di Gennaro Elena, Avallone Antonio, Budillon Alfredo

P1/33

A novel translatable method to evaluate the efficacy of drugs targeting KATP channels using cytofluorimetric DiBAC4(3) measurements in DIPG-36 cells

Di Turi Annamaria (Bari), Mezzina Giorgia, Denora Michele, Antonacci Marina, Tricarico Domenico

P1/34

Adavosertib-Mediated WEE1 Inhibition as a Strategy to Overcome Cisplatin Resistance in Non-Seminoma Testicular Cancer: Insights from Preclinical Models

Boldini Caterina (Brescia), Tamburello Mariangela, Abate Andrea, Salvi Valentina, Valcamonico Francesca, Suardi Nazareno Roberto, Mirabella Giuseppe, Altieri Barbara, Berruti Alfredo, Sigala Sandra

P1/35

Antiproliferative effects of mTOR inhibitors in pediatric gliomas

Grossi Flavia (Rome), Pizzoferrato Michela, Ferraro Chiara, Graziano Michela, Bono Silvia, Navarra Pierluigi, Lisi Lucia

P1/36

Effects of Rose Bengal-loaded Transfersomes on Triple Negative Breast Cancer Cells by Using Photodynamic Therapy

Cannas Claudia (Sassari), Puggioni Silvia, De Miglio Maria Rosaria, Schlich Michele, Gavini Elisabetta, Migheli Rossana

P1/37

Establishment of two new patient-derived ACC cell lines to enhance preclinical research models

Bonera Claudia (Brescia), Abate Andrea, Tamburello Mariangela, Baldelli Sara, Carini Mattia, Brugnoli Duilio, Leporati Marta, Cosseddu Domenico, Scatolini Maria, Inglesi Alessia, Laganà Marta, Cosentini Deborah, Tiberio Guido Alberto Massimo, Berruti Alfredo, Sigala Sandra

P1/38

Evaluating Synergistic Effects of Pepsertib and Low-Dose Doxorubicin in Leiomyosarcoma Through 3D Models

Simone Antonella (Bologna), Ravegnini Gloria, Montesi Monica, Panseri Silvia, Gorini Francesca, Coschina Emma, Benuzzi Eva, Angelini Sabrina, Hrelia Patrizia

P1/39

Evaluation of the cytotoxic effects of photoactivated actinomycin and sunitinib in colon cancer cell lines

Neggiani Giulia (Bologna), La Rosa Silvia, Greco Giulia, Turrini Eleonora, Mattioli Edoardo Jun, Calvaresi Matteo, Fimognari Carmela, Maffei Francesca

P1/40

MicroRNAs regulating NLRP3 inflammasome as key innovative markers in oral squamous cell carcinoma

D'Ariano Morena (Naples), Bello Ivana, Esposito Camilla, Panza Elisabetta

P1/41

New Analytical Strategy for Evaluating Nanoparticle Size-Dependent Pharmacokinetics and Biodistribution Profiles in 4T1 Tumor-Bearing Mice

J. Bulatova (Latvia), Antons Sizovs

P1/42

Targeting ERO1A for breast cancer treatment: a drug discovery study

Cherubini Alessandro (Urbino), Varone Ersilia, Marrazza Alice, Retini Michele, Chernorudskiy Alexander, Guidarelli Andrea, Mari Michele, Piersanti Giovanni, Bottegoni Giovanni, Cantoni Orazio, Zito Ester

P1/43

Targeting P2X7 receptor in glioblastoma multiforme: evaluating the antitumor effects of AZ10606120 on T98 cell line

Bono Silvia (Rome), Graziano Michela, Pizzoferrato Michela, Ferraro Chiara, Grossi Flavia, Navarra Pierluigi, Lisi Lucia

P1/44

The nicotinamide phosphoribosyltransferase (NAMPT) as a novel therapeutic target for the treatment of glioblastoma multiforme (GBM)

Buccellini Alessia (Pavia), Cassoni Mariachiara, Lanni Cristina, Galli Ubaldina, Travelli Cristina, Paolillo Mayra

P1/45

Association of glucagon-like peptide-1 receptor agonists with non-arteritic anterior ischaemic optic neuropathy: a disproportionality analysis of FDA adverse event reporting data

Balzano Nunzia (Naples), Di Napoli Raffaella, Anatriello Antonietta, Fraenza Federica, Sullo Maria Giuseppa, Mascolo Annamaria, Rafaniello Concetta, Capuano Annalisa

P1/46

Capmatinib and Tepotinib safety in patients with Non Small Cellular Lung Cancer (NSCLC): Real-World Data analysis from EudraVigilance

Speranza Desirée (Messina), Marafioti Mariapia, Cullotta Chiara, Silvestris Nicola, Santarpia Mariacarmela, Irrera Natasha

P1/47

Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with anti-CD20 monoclonal antibodies: a systematic review and meta-analysis of observational studies

Cagnotta Cecilia (Naples), Scavone Cristina, Sportiello Liberata, Maniscalco Giorgia Teresa, Ragone Angela, Frasca Mario, Rinaldi Barbara, Capuano Annalisa

P1/48

Medication review and deprescribing in hospitalized elderly patients: a retrospective observational study

De Stefano Alessandra (Salerno), Ricciardi Rosaria, Ciampa Claudia, Mazzeo Salvatore Maria, De Bellis Emanuela, Salvatore Vittorio, Conti Valeria, Filippelli Amelia

P1/49

Natural Language Processing and Social Networks in Pharmacovigilance: a systematic review

Gaio Mario (Naples), Zinzi Alessia, Cagnotta Cecilia, Cipriani Mattia, Cotrufo Alessandra, Ragone Angela, Naviglio Silvio, Perrella Alessandro, Capuano Annalisa, Rafaniello Concetta

P1/50

Osteosarcoma and Teriparatide: A Disproportionality Analysis using FAERS Database

Di Napoli Raffaella (Naples), Balzano Nunzia, Mascolo Annamaria, Laino Ludovica Vittoria, Scavone Cristina, Capuano Annalisa

P1/51

Pregnancy Recommendations Solely Based on Preclinical Evidence Should Be Integrated with Real-World Evidence: A Disproportionality Analysis of Certolizumab and Other TNF-Alpha Inhibitors Used in Pregnant Patients with Psoriasis

Gaio Mario, Vastarella Maria Giovanna, Sullo Maria Giuseppa, Scavone Cristina, Riccardi Consiglia (Naples), Campitello Maria Rosaria, Sportiello Liberata, Rafaniello Concetta

P1/52

The Role of the Clinical Pharmacologist in Optimizing the Care of HIV+ Patients Through Medication Review and Deprescribing

Donnarumma Danilo (Salerno), Pagano Annarita, De Bellis Emanuela, Zarrella Adele, Mazza Ines, Manzo Valentina, Charlier Bruno, Corbi Graziamaria, Masullo Alfonso, Madonia Simona, Mirella Onofrio, Filippelli Amelia, Pagliano Pasquale, Conti Valeria

P1/53

The unresolved case of the painkiller metamizole and its risk of agranulocytosis: a systematic review and a pharmacovigilance analysis from EudraVigilance database

Zinzi Alessia (Naples), Gaio Mario, Ruggiero Donatella, Riccardi Consiglia, Cagnotta Cecilia, Pentella Ciro, Capuano Annalisa, Rafaniello Concetta

P1/54

Modulation of Microglial Activation by mTOR Inhibitors in a Co-culture Model of Pediatric Glioblastoma

Ferraro Chiara (Rome), Graziano Michela, Pizzoferrato Michela, Bono Silvia, Grossi Flavia, Navarra Pierluigi, Lisi Lucia

P1/55

 α -PHP: acute effects and pharmacokinetic in male and female mice, and clinical data on related intoxications

Bassi Marta (Ferrara), Roda Elisa, Corli Giorgia, Bilel Sabrine, Bernardi Tatiana, Gregori Adolfo, Strano-Rossi Sabina, Locatelli Carlo Alessandro, Marti Matteo

Monday December 1st, 2025

Sala Maggiore

Oral Communication Session 5

Pain Pharmacology

Chairpersons: Luigi Francesco Iannone (Modena), Elena Lucarini (Florence)

- 9.00-9.15 **Mechanistic and proteomic insights into the protective action of ultramicronized palmitoylethanolamide in organotypic spinal cord slices under mast cell-driven neuroinflammation**
Toti Alessandra (Florence), Micheli Laura, Lucarini Elena, Margiotta Francesco, Ciampi Clara, Venturi Daniel, Cataldi Maria Giovanna, Trisolini Samuele, D'Amato Alfonsina, Di Cesare Mannelli Lorenzo, Ghelardini Carla
- 9.15-9.30 **Impairment of brain glymphatic system functionality in a murine model of oxaliplatin-induced neuropathic pain**
Ciampi Clara (Florence), Montagni Elena, Micheli Laura, Trisolini Samuele, Ghelardini Carla, Mascaro Anna Letizia Allegra, Di Cesare Mannelli Lorenzo
- 9.30-9.45 **Pharmacological blockage of neuroinflammatory cell signalling to modulate stress-induced mechanical and thermal pain sensitisation**
Fülöp Barbara (Hungary), Király Ágnes, Petrák Rebeka, Müller Júlia, Biró-Sütő Tünde, Kormos Viktória, Tékus Valéria, Rozmer Katalin, Dénes Ádám, Borbély Éva, Helyes Zsuzsanna
- 9.45-10.00 **The prokineticin system and glia cells as pharmacological targets to control neuroinflammation and to relieve neuropathic pain in a murine model of Fabry-Anderson disease**
Galimberti Giulia (Milan), Franchi Silvia, Amodeo Giada, Rullo Laura, Losarpio Loredana Maria, Riboldi Benedetta, Ceruti Stefania, Sacerdote Paola
- 10.00-10.15 **Targeting GLT-1 and PPAR- α : Dual Therapy with Ceftriaxone and PEA Alleviates Neuropathic Pain and Neuroinflammation in SNI Mice**
Teweldemedhin Milena Melake (Naples), Bonsale Roozbe, Perrone Michela, Belardo Carmela, Pagano Salvatore, Limongelli Rebecca, Iodice Viviana, Guida Francesca, Lungo Livio, Palazzo Enza, Maione Sabatino

- 10.15-10.30 **Antiallodynic effect of a formyl peptide receptor-1 ligand isolated from scorpion venom**
Pagano Salvatore (Naples), Manzo Iolanda, Limongelli Rebecca, Fusco Antimo, Guida Francesca, Belardo Carmela, Morace Andrea Maria, Perrone Michela, Ricciardi Federica, Srairi Najet, Infantino Rosmara, Palazzo Enza, Maione Sabatino, Luongo Livio
- 10.30-10.45 **Modulatory activity of N-palmitoyl-D-glucosamine in bridging gut dysbiosis and pain mechanisms**
Ricciardi Federica (Naples), Morace Andrea Maria, Fusco Antimo, Perrone Michela, Limongelli Rebecca, Lucà Stefano, Montella Marco, Pane Katia, Franzese Monica, Luongo Livio, Salvatore Marco, Maione Sabatino, Guida Francesca
- 10.45-11.00 **hiPSC-Derived Dorsal Root Ganglia Organoids: An *In vitro* Model to Uncover the Mechanisms of Diabetic Peripheral Neuropathy**
Venturi Daniel (Florence), Petrova Veselina, Powell Rasheen, Hakim Sara, Themistocleous Andreas C., Bennet David L., Woolf Clifford J.

Sala Artemisi

Oral Communication Session 6

Immunology meets Pharmacology (Joint Session with SIICA and EFIS)

Chairpersons: Valerio Ciccone (Siena), Bayram Talay Deniz (Turkey)

- 9.00-9.15 **Cracking the Tumor-Microenvironment Metabolic Code to Overcome Immune Escape and Reignite Antitumor Immunity**
Estevão Carlos Silva Barcelos, Andrea Marra, Giorgia Manni, Giada Mondanelli, Giulia Mencarelli, Doriana Ricciuti, Francesco Sarnari, Manola Mezzanotte, Benedetta Pieroni, Alessandro Pinzi, Anna La Rosa, Marco Colonna, Robert Schreiber, Peter J. Murray, Kenneth M. Murphy, Francesca Fallarino, Marco Gargaro (Perugia)
- 9.15-9.30 **Proteomic Profiling of the Colorectal Cancer Secretome: Immune Interactions and Clinical Implications**
Eleonora Timperi, Alessio Grimaldi (Rome), Claudia Montaldo, Mattia Laffranchi, Ombretta Melaiu, Manuela Antonioli, Ilenia Cammarata, Francesca Berardinilli, Carmine Mancone, Edoardo Maria Mutillo,

Valerio de Peppo, Raffaele Troiano, Paolina Saullo Spezi, Andrea Scarinci, Chiara D'Alterio, Maria Grazia Diodoro, Gian Maria Fimia, Antonio Ciardi, Stefania Brozzetti, Gianluca Grazi, Roberto Caronna, Piero Chirletti, Doriana Fruci, Giuseppe Giannini, Angela Gismondi, Silvano Sozzani, Marco Tripodi, Vincenzo Barnaba, Alessio Grimaldi

9.30-9.45

Transforming Growth Factor β Induced as a Novel Secreted Immune Checkpoint Counter-Inhibiting Human Tumor- Associated T Cells

Eleonora Timperi (Rome), Maria Manuela Rosado, Ombretta Melaiu, Sara Vitale, Sophie Bachy, Alessio Grimaldi, Mariachiara Corrado, Vanessa Mancini, Gabriela Leonti, Filippo Conti, Ilenia Cammarata, Ivana Celardo, Stephanie Kucykowicz, Gloryanne Aidoo-Micah, Daniele Accapezzato, Maria Del Ben, Valentina D'Oria, Cristiano De Stefanis, Laura Forcina, Fabrizio Maria Frattaroli, Andrea Picchetto, Massimo Chiaretti, Giancarlo D'Ambrosio, Giuseppe Giannini, Francesca Belardinelli, Andrea Scarinci, Gian Luca Grazi, Antonio Musarò, Mala K. Maini, Doriana Fruci, Micol E. Fiori, Ana Hennino, Vincenzo Barnaba

9.45-10.00

Pharmacological Impacts of NRAS Mutations in Drug-Resistant Acute Myeloid Leukaemia

Fiona M. Healy (UK), Vanessa Marensi, Patrycja M. Utnik, John F. Woolley, David J. MacEwan

10.00-10.15

Role of Glucocorticoid-Induced Leucine Zipper overexpression in Erythropoiesis

Cogliati Paolo (Perugia), Bereshchenko Oxana, Febo Marta, Di Scala Matilde, Braganti Lucrezia, Floridi Claudia, Martino Giovanni, Massoni Cristina, Migliorati Graziella, Mandarano Martina, Bruscoli Stefano

10.15-10.30

Pharmacological inhibition of necroptosis ameliorates multiorgan dysfunction in a murine model of sepsis

Ferreira Alves Gustavo (Camerino), Aimaretti Eleonora, Rubeo Chiara, Marzani Enrica, Porchietto Elisa, Einaudi Giacomo, Camillò Leonardo, Aragno Manuela, Cifani Carlo, Collino Massimo

10.30-10.45

Effects of palmitoylethanolamide (PEA) and luteolin on mild cognitive impairment: a randomized controlled clinical trial versus placebo

Procaccini Martina (Perugia), Cari Luigi, Boccardi Virginia, Pandolfi Anastasia, Alunno Martina, Cecchetti Roberta, Mecocci Patrizia, Nocentini Giuseppe

10.45-11.00

SIICA Junior Faculty activities and young EFIS network

Marco Gargaro (Perugia), Alessio Grimaldi (Rome), Eleonora Timperi (Rome)

Sala Felsina 1-2

Oral Communication Session 7

Cardiovascular and Metabolic

Chairpersons: Mariarosaria Bucci (Naples), Maria Antonietta Riemma (Naples)

- 9.00-9.15 **Defective protein persulfidation is involved in obesity associated skeletal muscle dysfunction: role of SIRT-1**
Casale Veronica (Naples), Smimmo Martina, D'Andrea Davide, Bello Ivana, Persico Gennaro, Panza Elisabetta, Friuli Marzia, Romano Adele, Papapetropoulos Andreas, Cirino Giuseppe, Bucci Mariarosaria, Filipovic Milos, Vellecco Valentina
- 9.15-9.30 **The Hybrid H₂S-Donor Metformin-Isothiocyanate (Met-Itc) preserves glycemic control while ameliorating vascular health**
Spezzini Jacopo (Pisa), Piragine Eugenia, Flori Lorenzo, Citi Valentina, Testai Lara, Barresi Elisabetta, Taliani Sabrina, Da Settimo Federico, Martelli Alma, Calderone Vincenzo
- 9.30-9.45 **Adenosine Pathway Characterization in a Rat Model of Heart Failure with Preserved Ejection Fraction**
Madonna Gennaro (Naples), Caiazzo Elisabetta, Riemma Maria Antonietta, Mele Elena, Telesca Marialucia, Donniacuo Maria, De Palma Giacomo, Cappetta Donato, Cicala Carla, Urbanek Konrad, Berrino Liberato, De Angelis Antonella, Ialenti Armando
- 9.45-10.00 **Cardioprotective effects of Simvastatin in Doxorubicin-Induced acute cardiomyocyte injury**
Vitale Roberta (Salerno), Mazzone Mariangela, Di Marcantonio Maria Carmela, Mincione Gabriella, Marzocco Stefania, Popolo Ada
- 10.00-10.15 **Protective Effect of Oleylethanolamide in Obesity-Induced Cardio-Renal-Metabolic Alterations**
Comella Federica (Naples), Pirozzi Claudio, Aragon Herrera Alana, Melini Stefania, Opallo Nicola, Navatti Nicole Pia, Meli Rosaria, Lago Francisca, Mattace Raso Giuseppina

- 10.15-10.30 **Metabolic and Cardiovascular Protection by Sacubitril/Valsartan alone or in combination with Dapagliflozin in Age-Related HFpEF**
Mele Elena (Naples), Riemma Maria Antonietta, Donniacuo Maria, Telesca Maria Lucia, Sorrentino Grazia, Ahmed Eisa A. Kamal, Urbanek Konrad, Cappetta Donato, Berrino Liberato, Rossi Francesco, De Angelis Antonella
- 10.30-10.45 **Effect of elexacaftor/tezacaftor/ivacaftor therapy on serum lipoproteins functions in adults with cystic fibrosis**
Palumbo Marcella (Parma), Greco Claudia, Zimetti Francesca, Adorni Maria Pia, Ruscica Massimiliano, Blasi Francesco, Gramegna Andrea
- 10.45-11.00 **Real-world use of direct oral anticoagulants in atrial fibrillation patients with moderate/severe chronic kidney disease: a propensity score-matched analysis from the START registry**
Gazzaniga Gianluca (Rome), Menichelli Danilo, Poli Daniela, Palareti Gualtiero, Antonucci Emilia, Pani Arianna, Pignatelli Pasquale, Pastori Daniele

Sala Foyer

Oral Communication Session 8

Neuropsychopharmacology II

Chairpersons: Silvana Gaetani (Rome), Ramona Meanti (Milan)

- 9.00-9.15 **Unveiling the Role of RNF10 in Synaptic Plasticity and Behavioural Flexibility through GluN2A-Dependent Signalling**
Romito Elena (Milan), Carrano Nicolò, Ribeiro Ana, Italia Maria, La Greca Filippo, Genova Francesca, D'Andrea Laura, Zianni Elisa, Soulttan Khaled, Barthet Gael, Mitro Nico, Mulle Christophe, Marcello Elena, Gardoni Fabrizio, DiLuca Monica, Scheggia Diego
- 9.15-9.30 **Metabolic stress-response in female rats: b-oxidation-induced vulnerability vs adaptive resilience**
Brivio Paola (Milan), Pedretti Silvia, Gallo Maria Teresa, Palumbo Arianna, Cruca Piotr, Lason Magdalena, Litwa Ewa, Fumagalli Fabio, Papp Mariusz, Mitro Nico, Calabrese Francesca

- 9.30-9.45 **FAAH inhibition mitigates neurochemical alterations triggered by chronic social isolation in rats**
Eramo Barbara (Rome), Santoro Martina, Friuli Marzia, Schiavone Stefania, Romano Adele
- 9.45-10.00 **Lifelong Sulforaphane Diet Attenuates Behavioural and Cortical Dysfunctions in Male and Female BTBR Mouse Model of Autism Spectrum Disorders**
Sikora Vladyslav (Foggia), Bove Maria, Santoro Martina, Tucci Paolo, Trabace Luigia
- 10.00-10.15 **The novel NOP receptor ligand Sunobinop: an *in vitro* pharmacological characterization**
Camilotto Riccardo (Padua), Malfacini Davide, Pietro Pola, Morrone Erika, Frezza Alessia, Ramalingan Rahul, Sturaro Chiara, Pacifico Salvatore, Ruzza Chiara, Guerrini Remo, Whiteside Garth, Calò Girolamo
- 10.15-10.30 **Disruption of the BDNF-KCC2–Allopregnanolone Pathway Drives GABA-A Polarity Shift and Executive Dysfunction Induced by Sleep Deprivation**
Concas Luca (Siena), Serra Valeria, Scheggi Simona, Melis Miriam, Bortolato Marco, Frau Roberto
- 10.30-10.45 **Towards new therapies for KCNA2-related neurodevelopmental disorders: a drug repurposing study using virtual screening and automated patch clamp**
Marinelli Manuel (Bari), Cerchiara Alessandro Giovanni, Tondo Anna Rita, Arigliano Claudia, Rubino Egidio Maria, Trisciuzzi Daniela, Dinoi Giorgia, Mele Antonietta, Siragusa Lydia, Liantonio Antonella, Nicolotti Orazio, De Luca Annamaria, Imbrici Paola
- 11.00-11.30 Coffee break

Sala Felsina 1-2

11.30-12.15

Workshop

Chairperson: Monica DiLuca (Milan)

Principles and Critical Issues in the Preclinical and Clinical Evaluation Process of New Drugs

Patrizia Popoli (Rome)

12.15-13.00

Workshop

Chairperson: Carla Ghelardini (Florence)

Basic Principles of Technology Transfer: Possible Applications in Drug Development

Filippo Caraci (Catania)

13.30-15.00

Lunch

15.00-15.30

Workshop Farmindustria

Chairperson: Giuseppe Cirino (Naples)

Pharmaceutical Industry Careers: What Young Pharmacologists Need to Know

Marco Zibellini (Rome)

15.30-16.30

Workshop SiMeF

Chairperson: Silvana Gaetani (Rome)

From Passion to Profession: Careers in Pharmaceutical Medicine

Marisa Le Donne (Rome), Mario Spione (Rome)

In collaborazione con Mario Mangrella (Milan), Luca Miglierina (Milan), Simona Paratore (Rome)

16.30-17.00

Coffee break

Sala Maggiore

Oral Communication Session 9

Pharmacognosy, Phytotherapy and Nutraceuticals

Chairperson: Lorenzo Flori (Pisa), Agnese Graziosi (Milan)

- 17.00-17.15 **Combining the natural compounds lupeol and phytol with chemotherapeutic drugs to overcome multidrug resistance in tumor models with innate and acquired resistance**
Cusimano Alessandra (Palermo), Augello Giuseppa, Cusimano Antonella, Labbozzetta Manuela, Cervello Melchiorre, Notarbartolo Monica, Poma Paola
- 17.15-17.30 **Naringenin rescues autophagy, lysosomal and LDs homeostasis in SPG4 Hereditary Spastic Paraplegia model**
Guarato Giulia (Padua), Fallaha Alice, Vantaggiato Chiara, Brivio Francesca, Marziali Aurora, Napoli Barbara, Gumeni Sentiljana, Orso Genny
- 17.30-17.45 **Cytoprotective properties of *Castanea sativa* (Mill.) by-products in human gastric cells and role of *in vitro* digestion**
Percaccio Ester (Rome), Piazza Stefano, Sangiovanni Enrico, Di Giacomo Silvia, Di Sotto Antonella
- 17.45-18.00 **The second life of *Citrus bergamia*: Bioavailability analysis of a new formulation using waste-based microencapsulation as valuable source of bioactive compounds**
Serra Maria (Catanzaro), Roberta Macri, Bonacci Sonia, Giovanna Ritorto, Ussia Sara, Nucera Saverio, Caminiti Rosamaria, Ruga Stefano, Altomare Carmen, Tucci Luigi, Trunfio Giuseppe, Cosco Donato, Procopio Antonio, Muscoli Carolina, Mollace Rocco, Mollace Vincenzo

Sala Maggiore

Oral Communication Session 10

Rare Diseases and Orphan Drugs

Chairpersons: Maria Antonietta Barbieri (Messina), Maria Antonietta Riemma (Naples)

- 18.00-18.15 **A preclinical investigation in D2-mdx murine model of Duchenne muscular dystrophy shows a potential involvement of complement cascade components in triggering inflammation and fibrosis**
Tulimiero Lisamaura (Bari), Boccanegra Brigida, Mantuano Paola, Lenti Roberta, Marinelli Manuel, Cappellari Ornella, De Luca Annamaria
- 18.15-18.30 **Erucin preserves skeletal muscle health in Duchenne Muscular Dystrophy**
Smimmo Martina (Naples), Casale Veronica, D'Andrea Davide, Persico Gennaro, Cirino Giuseppe, Filipovic Milos, Bucci Mariarosaria, Vellecco Valentina
- 18.30-18.45 **ATM knock out human neural progenitor cells: a valuable model for better understanding of Ataxia Telangiectasia pathophysiology and for drug repurposing**
Boni Giulia (Novara), Pessolano Emanuela, Dematteis Giulia, D'Angelo Camilla, Lim Dmitry, Robotti Elisa, Grilli Mariagrazia
- 18.45-19.00 **Patient-specific neural stem cells and neurons as an *in vitro* models for screening drug safety and efficacy for Aicardi-Goutières pediatric patients**
Pugnetti Letizia (Trieste), Zudeh Giulia, Lucafò Marianna, Di Filippo Dalila, Ferraro Rosalba Monica, Franca Raffaella, Tommasini Alberto, Giliani Silvia, Gabriele Stocco

Sala Artemisi

Oral Communication Session 11

Pharmacology of Integrated Systems

Chairpersons: Elena Lucarini (Florence), Eleonora Timperi (Rome)

- 17.00-17.15 **Uncovering the molecular mechanisms of thiopurine-induced pancreatitis: a patient-specific iPSC-based study**
Rispoli Paola (Trieste), Genova Elena, Yue Fengming, Ferraro Rosalba Monica, Bramuzzo Matteo, Decorti Giuliana, Lucafò Marianna, Stocco Gabriele
- 17.15-17.30 **Impact of pediatric enteroid culture method on nutrient and xenobiotic transporter expression**
Vicky L. Sun, Kai Wang, Edward J. Kelly, Samuel L.M. Arnold (USA)
- 17.30-17.45 **Epithelium-to-neuron signaling contributes to dysbiosis-associated visceral hypersensitivity: insights from a colon organoid-based system to highlight new pharmacological targets**
Margiotta Francesco (Florence), Lucarini Elena, Toti Alessandra, Cataldi Maria Giovanna, Trisolini Samuele, Curti Lorenzo, Masi Alessio, Mello Tommaso, Le Gall Gwenaelle, Mattei Gianluca, Magi Alberto, Vauzour David, Mannaioni Guido, Di Cesare Mannelli Lorenzo, Ghelardini Carla
- 17.45-18.00 **Therapeutic potential of combined P2X4 and P2X7 inhibition in an experimental model of colitis**
Di Salvo Clelia (Pisa), Valdiserra Giulia, Fornai Matteo, Pellegrini Carolina, Adinolfi Elena, Dal Ben Diego, Antonioli Luca
- 18.00 -18.15 **Gut inflammation promotes cognitive decline via NLRP3 pathway in a murine model of Alzheimer's disease**
Valdiserra Giulia (Pisa), Antonioli Luca, Fornai Matteo, Di Salvo Clelia, Pierucci Clarissa, D'Antongiovanni Vanessa, Marini Elisabetta, Bertinaria Massimo, Bernardini Nunzia, Pellegrini Carolina
- 18.15-18.30 **Inhaled siRNA Delivery for Pulmonary Fibrosis: CD105 as a Promising Molecular Target**
Esposito Erika (Naples), Indolfi Chiara, Correale Melania, Brusco Susy, Mitidieri Emma, Costabile Gabriella, Ungaro Francesca, Sorrentino Raffaella, d'Emmanuele di Villa Bianca Roberta

- 18.30-18.45 **Selective PROTAC-mediated HDAC6 degradation reverses TGF- β 1-induced fibrotic remodeling in human lung fibroblasts**
Ciccone Valerio (Siena), Carullo Gabriele, Cursaro Ilaria, Gemma Sandra, Butini Stefania, Campiani Giuseppe, Donnini Sandra, Morbidelli Lucia
- 18.45-19.00 **Gallic acid released from the BTK RIGENERA BCP biomaterial coated with layered double hydroxide prevents osteoclast differentiation *in vitro***
Suvieri Chiara (Perugia), Bastianini Maria, Pagano Stefano, Marinucci Lorella, Ambrogi Valeria, Pallotta Maria Teresa, Sisani Michele, Belladonna Maria Laura

Sala Felsina 1-2

Oral Communication Session 12

Cancer Pharmacology II

Chairpersons: Marianna Moro (Novara), Arianna Pani (Milan)

- 17.00-17.13 **Ironing Out Medulloblastoma: Targeting lactate import to enhance ferroptosis sensitivity**
Manfreda Lorenzo (Padua), Camponogara Rachele, Marzullo Bryan, Breda Franco, Rampazzo Elena, Savino Angela Maria, Tennant Danie, Viola Giampietro, Persano Luca, Bortolozzi Roberta
- 17.13-17.26 **Troloxerutin potentiated Temozolomide treatment in human glioblastoma multiforme cell line**
Calcaterra Elsa (Messina), Mannino Deborah, Scuderi Sarah, Campolo Michela, Paterniti Irene, Esposito Emanuela
- 17.26-17.39 **Targeting homologous recombination in cancer through computationally-designed DNA aptamers: a new frontier in synthetic lethality-based therapies**
Masi Mirco (Genoa), Varignani Giulia, Milordini Giulia, Zacco Elsa, Armaos Alexandros, Di Palma Francesco, Giloid Martina, Rupert Jacob, Broglia Laura, Oneto Michele, Scotto Marco, Marotta Roberto, Tartaglia Gian Gaetano, Giroto Stefania, Cavalli Andrea

- 17.39-17.52 **Taming Transcriptional Rewiring with TRAFACs**
Boumya Sara (Turin), Tino Azzurra, Trusolino Livio, Genazzani Armando, Serafini Marta
- 17.52-18.05 **Genetic deletion of TRPV3 promotes the progression of colitis-associated cancer**
Miraglia Maria (Naples), Cicia Donatella, Iaccarino Nunzia, Amico Rebecca, De Cicco Paola, Rinaldi Maria Michela, Nanì Maria Francesca, Randazzo Antonio, Capasso Raffaele, Cattaneo Fabio, Izzo Angelo Antonio, Pagano Ester
- 18.05-18.18 **From Flat to Functional: Advancing Endometrial Cancer Models Through 3D Bioprinting**
Coschina Emma (Bologna), Ravegnini Gloria, Gorini Francesca, Benuzzi Eva, Simone Antonella, Angelini Sabrina, Simonsson Stina, Hrelia Patrizia
- 18.18-18.31 **Circulating innate lymphoid cells are dysregulated in patients with prostate cancer**
Maresca Daniela Claudia (Naples), La Civita Evelina, Romano Benedetta, Ambrosio Maria Rosaria, Somma Fabio, Wyss Tania, Rocco Bernardo, Rubino Valentina, Cari Luigi, Krebs Philippe, Rodriguez-Calero Antonio, Ferro Matteo, Trabanelli Sara, Jandus Camilla, Crocetto Felice, Ianaro Angela, Terracciano Daniela, Ercolano Giuseppe
- 18.31-18.44 **Light irradiation potentiates the cytotoxic effects of curcumin analogs in cancer cells**
Greco Giulia (Bologna), Turrini Eleonora, Belluti Federica, Calvaresi Matteo, Ferrini Fabio, Sestili Piero, Fimognari Carmela
- 18.44-19.00 ***In vitro* analysis of the cytotoxic potential of organic cyanobacterial extracts from the Bagni San Filippo thermal waters on cancer cells**
La Rosa Silvia (Bologna), Turrini Eleonora, Esposito Germana, Costantino Valeria, Fimognari Carmela

Sala Foyer

Oral Communication Session 13

Neuropharmacology and Addiction Disorders

Chairpersons: Marco Pistis (Cagliari), Sikora Vladyslav (Foggia)

- 17.00-17.15 **Integrated approaches in the FTD/GRN Model: Behavior, Molecular Pathways, and Gene Therapy Devices**
Bertasini Chiara (Verona), Italia Maria, Picari Rozalda, Tavakolian Haghighi Shima, Piva Alessandro, Chiamulera Cristiano, Wahlberg Lars U., Scheggia Diego, Gardoni Fabrizio, Paolone Giovanna
- 17.15-17.30 **PEA-OXA restores cognitive impairments associated with vitamin D deficiency-dependent alterations of the gut microbiota**
Perrone Michela (Naples), Guida Francesca, Iannotta Monica, Belardo Carmela, Fusco Antimo, Marabese Ida, Manzo Iolanda, Di Martino Emanuele, Pagano Salvatore, Boccella Serena, Giorgini Giada, Silvestri Cristoforo, Infantino Rosmara, Luongo Livio, Di Marzo Vincenzo, Maione Sabatino
- 17.30-17.45 **High-fat-diet-induced brain insulin resistance dampens GLUT4 cerebral expression and impairs neuronal plasticity**
Cifarelli Lorenzo (Turin), Aimaretti Eleonora, Darsalia Vladimer, Vercalsteren Ellen, Oberto Alessandra, Bertocchi Ilaria, Patrone Cesare, Luzzati Federico, Collino Massimo
- 17.45-18.00 **Prolonged nicotine exposure, via electronic cigarettes, selectively enhances the transcription of Bdnf/TrkB and elevates dynorphin peptide and OLIG2 levels in the rat VTA**
Morosini Camilla (Bologna), Laura Rullo, Losapio Loredana, Vivarelli Fabio, Paolini Moreno, Canistro Donatella, Candeletti Sanzio, Romualdi Patrizia
- 18.00-18.15 **Stress-induced vulnerability in cocaine-withdrawn adolescent rats involves microglial dysfunctions and excitatory-inhibitory unbalance in the hippocampus**
Mottarlini Francesca (Milan), Miglioranza Paolo, Parolaro Susanna, Rizzi Beatrice, Taddini Sofia, Caffino Lucia, Fumagalli Fabio

- 18.15-18.30 **A novel lamotrigine-derivative compound as potential candidate in the treatment of epilepsy: a functional *in vitro* study**
Coppola Maria Antonietta (Genoa), Baro Eloy Lozano, Catta Federica, Mazza Irene, Pusch Michael, Ghashghaei Ouldouz, Lavilla Rodolfo, Gavazzo Paola
- 18.30-18.45 **Chronic Administration of Sub-Perceptual Psilocybin Enhances Visual Rehabilitation Post-Occipital Stroke in Mice**
Nasini Sofia (Padua), Barzon Bendetta, Casile Antonino, Cambiaghi Marco, De Martin Sara, Mattarei Andrea, Pappagallo Marco, Manfredi Paolo, Comai Stefano
- 18.45-19.00 **Fluoxetine reverses ethanol-induced anxiety via region-specific modulation of 2-AG and LPA signalling in male rats**
Castro-Zavala Adriana (Spain), Sanchez-Marin Laura, Boonen Kirstin, Rodriguez de Fonseca Fernando, Serrano Antonia

19.00-20.30**Poster Session 2 - Poster Area Garisenda-Riccadonna**

Chairpersons: Stefano Agliardi (Milan), Vincenzo Calderone (Pisa), Annalisa Capuano (Naples), Valerio Ciccone (Siena), Giulia Greco (Bologna), Alice Marino (Belgium), Elena Lucarini (Florence), Marco Pistis (Cagliari), Federica Ricciardi (Naples)

P2/1**Bergamot essential oil as a potential therapeutic agent for inflammatory bowel disease: phytochemical profile, toxicity assessment, and anti-inflammatory effects**

Genovesi Gianluca (Chieti), Centulio Angelica Pia, Ciaramellano Davide, Acquaviva Alessandra, Libero Maria Loreta, Di Simone Simonetta Cristina, Tunali Fatma, Leone Sheila, Recinella Lucia, Chiavaroli Annalisa, Ferrante Claudio, Menghini Luigi, Brunetti Luigi, Orlando Giustino

P2/2**Glucosinolates and isothiocyanates from plants of the Brassicaceae family: defining their amount in different plants and their bioaccessibility after ingestion**

Galgani Giulia (Pisa), Calderone Vincenzo, Moreno Fernandez Diego Angel

P2/3**Impact of microbial-assisted cultivation on the phytochemical and biological properties of *Salvia rosmarinus* Spenn.: a biotechnological approach to medicinal plants**

Baldani Claudia (Rome), De la Fuente-Gonzalez Elena, Gutierrez-Manero Javier, Ramos-Solano Beatriz, Di Sotto Antonella

P2/4

***In vitro* investigation of the possible toxicological mechanisms behind the adverse reactions of *Garcinia cambogia* (Gaertn.) Desr. extracts in human cholangiocytes**

Corsetti Letizia (Rome), Percaccio Ester, Mazzanti Gabriela, Di Giacomo Silvia, Di Sotto Antonella

P2/5

Beneficial effects of Bromelain combined with N-Acetylcysteine: a promising approach for the treatment of urinary tract infections

Ciaramellano Davide (Torrevecchia Teatina), Angelica Pia Centulio, Genovesi Gianluca, Loreta Libero Maria, Acquaviva Alessandra, Pinti Morena, Di Lodovico Silvia, Recinella Lucia, Orlando Giustino, Ferrante Claudio, Menghini Luigi, Di Simone Simonetta Cristina, Leone Sheila, Brunetti Luigi

P2/6

***In vitro* innovative peptide-based biosensor as a diagnostic tool to identify JAKs tyrosine kinase activity in primary cells of pediatric patients affected by rare-immuno mediated diseases**

Parmesan Nicole (Trieste), Franca Raffaella, Pugnetti Letizia, Rispoli Paola, Muzzo Antonella, Taddio Andrea, Tommasini Alberto, Stocco Gabriele

P2/7

Early assessment of IL8 and PD1+ Treg predicts response and guides treatment monitoring in cemiplimab-treated cutaneous squamous cell carcinoma

Somma Fabio (Naples), Maresca Daniela Claudia, Formisano Luigi, Ianaro Angela, Ercolano Giuseppe

P2/8

A Bioactive Botanical Supplement Mitigates Microglial Activation and Preserves BBB Integrity *In vitro*

Camillò Leonardo (Turin), Capitani Lara, Marzani Enrica, Bastianello Angelica, Algeri Alessandro, Spampinato Simona Federica, Collino Massimo

P2/9

Achillea erba-rota* subsp. *moschata* extract preserves blood-brain barrier integrity and reduces neuroinflammation *in vitro

Mercuriali Benedetta (Milan), Bottoni Martina, Milani Fabrizia, Muluhie Majeda, Giuliani Claudia, Rzemieniec Joanna, Castiglioni Laura, Fico Gelsomina, Sironi Luigi

P2/10

Biological mechanisms linking childhood trauma to anxiety: the interplay between emotion regulation and inflammatory signatures

Bottanelli Chiara (Milan), Rosa Melissa, Mombelli Elisa, Genini Patrizia, De Cillis Floriana, Tura Giovanni Battista, Martinelli Alessandra, Catteneo Annamaria

P2/11

CD73 regulation in psoriasis: insights from an *in vitro* approach

Giraulo Caterina (Salerno), De Palma Giacomo, Plaitano Paola, Esposito Roberta, Morretta Elva, Monti Maria Chiara, Cicala Carla, Morello Silvana

P2/12

CNSL-Based Liposomes: A Promising Anti-Inflammatory and Wound-Healing Strategy for Inflammatory Skin Conditions

Cimetti Chiara (Bologna), Martinengo Bianca, Batani Gessica, Gioran Anna, Chondrogianni Niki, Sansone Anna, Ferreri Carla, Bolognesi Maria Laura, Baiula Monica

P2/13

Effects of two mTOR inhibitors on human microglial activation in response to inflammatory stimulation

Graziano Michela (Rome), Pizzoferrato Michela, Ferraro Chiara, Grossi Flavia, Bono Silvia, Navarra Pierluigi, Lisi Lucia

P2/14

Glucocorticoids Modulate Extracellular Vesicle Production and Immune Signaling in Jurkat and THP-1 Cells

Frolkov Artemii (Perugia), Santoro Daniele, Febo Marta, Cogliati Paolo, Braganti Lucrezia, Romani Rita, Migliorati Graziella, Bruscoli Stefano, Bereshchenko Oxana

P2/15

Leukocyte Integrins Targeting Ligands as an Innovative Therapeutic Approach for the Treatment of Inflammatory-based Diseases

Maurizio Andrea (Bologna), Giraldi Valentina, Giacomini Daria, Baiula Monica

P2/16

Neurosteroid pregnenolone protects HMC3 microglial cells against lps-induced neuroinflammation

Sartori Emma (Milan), Criscione Maria Laura, Rizzi Laura, Bresciani Elena, Torsello Antonio Biagio, Meanti Ramona

P2/17

Neutralization of eNAPRT Improves Outcomes in a Mouse Model of Sepsis

Sosic Zlata A. (Camerino), Ferreira Alves Gustavo, Aimaretti Eleonora, Camillo Leonardo, Collino Massimo, Genazzani Armando

P2/18

New Insights on the miRNA Role in Diabetic Tendinopathy: Adipose-Derived Mesenchymal Stem Cell Conditioned Medium as a Potential Innovative Epigenetic-Based Therapy for Tendon Healing

Russo Marina (Naples), Lepre Caterina Claudia, Conza Gianluca, Tangredi Nicoletta, D'Amico Giovanbattista, Braile Adriano, Moretti Antimo, Tarantino Umberto, Gimigliano Francesca, D'Amico Michele, Trotta Maria Consiglia, Toro Giuseppe

P2/19

Novel Hydrogen Sulfide Donors from the Sea: Exploring New Therapeutic Perspectives

Indolfi Chiara (Naples), Correale Melania, Bello Ivana, Esposito Camilla, Esposito Erika, Casertano Marcello, Imperatore Concetta, Menna Marialuisa, Sorrentino Raffaella, Panza Elisabetta, d'Emmanuele di Villa Bianca Roberta, Mitidieri Emma

P2/20

Pharmacologically targeting CDK9 in sepsis: effects on neuroinflammation and blood brain barrier disruption

Marzani Enrica (Turin), Ferreira Alves Gustavo, Aimaretti Eleonora, Porchietto Elisa, Camillò Leonardo, Cifani Carlo, Spampinato Simona Federica, Collino Massimo

P2/21

Use of progesterone as add-on therapy for the treatment of neuroinflammation in drug-resistant epilepsy

Criscione Maria Laura (Milan), Sartori Emma, Rizzi Laura, Bresciani Elena, Torsello Antonio, Meanti Ramona

P2/22

Amyloid- β -induced neuroinflammation impairs oligodendrocyte maturation via microglial activation

Chemello Chiara (Padua), Scarin Natasha, De Lorenzi Ersilia, Khalid Ayesha, Facci Laura, Scuderi Caterina, Guidolin Diego, Zusso Morena

P2/23

Astrocyte-mediated oligodendrocyte dysfunction induced by A β 1-42 is prevented by co-ultramicrosized palmitoylethanolamide/luteolin *in vitro*

Ciarla Claudia (Rome), Facchinetti Roberta, Burla Silvia, Valenza Marta, Scuderi Caterina

P2/24

Brain Boosters from Cannabis: CBGA and CBDA show promise in beating memory loss

Limongelli Rebecca (Naples), Vitale Rosa Maria, Morace Andrea Maria, Ricciardi Federica, Fusco Antimo, Boccella Serena, Guida Francesca, Iannotti Fabio Arturo, Luongo Livio, Amodeo Pietro, Maione Sabatino

P2/25

Complement Proteins Induce Glutamate Transporter Reversal and Promote Synaptic Imbalance in a Mouse Model of Multiple Sclerosis

Rosenwasser Nicole (Genoa), Torre Veronica, Taddeucci Alice, Olivero Guendalina, Pittaluga Anna

P2/26

Effects of trehalose treatment on gene and protein expression in an Infantile Neuronal Ceroid Lipofuscinosis *in vitro* model: focus on autophagy, neurogenesis and voltage-gated ion channels

Carbone Gaia (Bari), Canfora Vittoria, Camerino Giulia Maria

P2/27

Potential protective effects of leptin on neuronal excitability alterations in Alzheimer's disease

Magliocca Giorgia (Naples), Piccialli Ilaria, Esposito Emilia, Pannaccione Anna

P2/28

Sex-dependent chaperone-assisted selective autophagy activity in ALS astrocytes and microglia

Rosso Francesca (Genoa), Magdalena Rocio, Torazza Carola, Bacchetti Francesca, Brodnanova Maria, Bonanno Giambattista, Poletti Angelo, Milanese Marco, Cristofani Riccardo, Bonifacino Tiziana

P2/29

Sigma-1R: a key protein modulating Ca²⁺ organelles interplay in neurodegeneration

Ciancio Raffaella (Naples), Tedeschi Valentina, Piccirillo Silvia, Pannaccione Anna, Secondo Agnese

P2/30

Synergistic effects of citicoline and CoQ10 against oxidative stress in rat astrocytes

Centulio Angelica Pia (Chieti), Ciaramellano Davide, Genovesi Gianluca, Leone Sheila, Recinella Lucia, Libero Maria Loreta, Acquaviva Alessandra, Orlando Giustino, Chiavaroli Annalisa, Ferrante Claudio, Menghini Luigi, Di Simone Simonetta Cristina, Brunetti Luigi

P2/31

Targeting NSC Metabolism to Promote Neurogenesis in Alzheimer's Disease

Terenzi Valentina (Ancona), Cerqueni Giorgia, Serfilippi Tiziano, Prezioso Alessandra, Piccirillo Silvia, Magi Simona, Secondo Agnese, Lariccia Vincenzo

P2/32

Timing matters: How daily rhythms affect neuroprotection therapy for stroke

Licastro Ester (Naples), Viscardi Viviana, Cuomo Ornella, Hayakawa Kazuhide, Lo Eng H, Esposito Elga, Pignataro Giuseppe

P2/33

Genotype-phenotype-drug response correlation of newly identified SCN1A variants from the Italian Registry of Dravet Syndrome Residras

Dinoi Giorgia (Bari), Arigliano Claudia, Mei Davide, Canfora Ileana, Rubino Egidio Maria, Parrini Elena, Conte Elena, Scirucchio Vittorio, Balestrini Simona, Guerrini Renzo, Liantonio Antonella, De Luca Annamaria, Imbrici Paola

P2/34

Novel insights into ATM function in skeletal muscle cells

Lecchi Giulia (Novara), Dematteis Giulia, Lim Dmitry, Talmon Maria, Fresu Luigia Grazia

P2/35

Validation of a 3D skeletal muscle organoid model of Duchenne muscular dystrophy as a drug screening platform for patient oriented *in vitro* studies

Quarta Raffaella (Bari), Han Mitchell, Cristiano Enrica, Marinelli Manuel, Mouly Vincent, Gaio Nikolas, Cappellari Ornella, De Luca Annamaria

P2/36

Chronic restraint stress affected the whole body metabolism in adult male rats: the role of ventral hippocampus and hypothalamus

Palumbo Arianna (Milan), Brivio Paola, Pedretti Silvia, Gallo Maria Teresa, Fumagalli Fabio, Mitro Nico, Calabrese Francesca

P2/37

Dissecting GluA3's role in synaptic plasticity and neuronal morphology

Spinola Alessio (Milan), Italia Maria, Caruso Sofia, Gomez Blanco José Ignacio, Pelucchi Silvia Cecilia, Zianni Elisa, Marcello Elena, Di Luca Monica, Gardoni Fabrizio

P2/38

Effects of pharmacological inhibition of endocannabinoid transporter during prenatal life on rat dopamine neuronal activity and social behavior

Coraddu Camilla (Cagliari), Serra Valeria, Carli Marco, Traccis Francesco, Melis Miriam

P2/39

Enhancing traumatic memory extinction via targeted optogenetic modulation of infralimbic projections

Conforti Elvira (Rome), Chiacchierini Giulia, Volpi Isabella, Morena Maria, Campolongo Patrizia

P2/40

Experimental autoimmune encephalomyelitis in mice leads to a depressive-like phenotype: involvement of serotonin and N-Acetyl serotonin pathways

Palmieri Rossella Pia (Foggia), Monaco Martina, Sacconi Paride, Mastio Andrea, Pittaluga Anna Maria, Trabace Luigia, Sagheddu Claudia, Oliviero Guendalina

P2/41

Investigating the behavioral and molecular impacts of the expression of the humanized ACE2 receptor in a murine strain. New perspectives in the field of Neuroscience

Siddi Carlotta (Cagliari), Scherma Maria, Dedoni Simona, Ristaldi Maria Serafina, Porcu Susanna, Marongiu Maria Franca, Vaccargiu Simona, Pinna Ilenia, Tsai Ching Yen, Fadda Paola

P2/42

Long-term impact of adolescent cannabidiol (CBD) exposure on neuronal markers and dendritic spines in female rats

Vimercati Mattia (Busto Arsizio), Gabaglio Marina, Rubino Tiziana, Zamberletti Erica

P2/43

Melatonin MT2 receptors activation attenuates MK-801-induced schizophrenia-like effects

Barzon Benedetta (Padua), Marchiotta Federica, Nasini Sofia, Casile Antonino, Cifani Carlo, Gobbi Gabriella, Cambiaghi Marco, Comai Stefano

P2/44

Possible role of monoaminergic transmission and tryptophan metabolism alterations in early experimental autoimmune encephalitis anhedonia symptoms

Saccani Paride (Genoa), Mastio Andrea, Palmeri Rossella Pia, Torre Veronica, Rosenwasser Nicole, Monaco Martina, Pittaluga Anna, Trabace Luigia, Pistis Marco, Morgese Maria Grazia, Sagheddu Claudia, Olivero Guendalina

P2/45

Rabphilin3A: From NMDA receptor synaptic retention to neurodevelopmental disorders

Barzasi Marta (Milan), Spinola Alessio, Galizia Chiara, Pavinato Lisa, Brusco Alfredo, DiLuca Monica, Gardoni Fabrizio

P2/46

Screening of a chemical library for the Neuropeptide S receptor using the calcium mobilization assay

Pizzolitto Alice (Padua), Simon Katharina, Negrini Solimano Marco, Argentieri Michela, Mariotto Elena, Bortolozzi Roberta, Marzola Erika, Ruzza Chiara, Reinscheid Rainer K., Guerrini Remo, Malfacini Davide, Calò Girolamo

P2/47

Sex-specific neuroprotective effects of ketogenic diet in a rodent model of early-life stress

Marchesin Alessia (Milan), Begni Veronica, Precetti Federica, Cattaneo Annamaria, Riva Marco Andrea

P2/48

Targeting endocannabinoid tone reverses PTSD-associated social impairments in adolescent rats

Lisiola Jacopo Maria (Rome), Mancini Giulia Federica, Conforti Elvira, Mariani Federica, Salvi Emanuele, Lloyd Luz Maria, Morena Maria, Campolongo Patrizia

P2/49

Role of the lateral hypothalamus in the hyperdopaminergic phenotype induced by prenatal THC exposureSerra Valeria (Cagliari), Melis Miriam

P2/50

N-acylethanolamines mixture improves metabolic fat-to-heart crosstalk in obesity: preclinical evidenceNavatti Nicole Pia (Naples), Melini Stefania, Opallo Nicola, Comella Federica, Mattace Raso Giuseppina, Pirozzi Claudio, Meli Rosaria

P2/51

Olaliamid® mitigates hypothalamic dysregulation in a rat model of diet-induced metabolic syndromeBurla Silvia (Rome), Ciarla Claudia, Facchinetti Roberta, Di Cesare Benedetta, Valenza Marta, Campolongo Patrizia, Scuderi Caterina

P2/52

Pharmacological modulation of the paracannabinoid system as a protective strategy against high-fat diet-induced autophagy dysregulationCampagna Alessia (Rome), Friuli Marzia, Sepe Christian, Eramo Barbara, Panza Elisabetta, Bello Ivana, Gaetani Silvana, Romano Adele

P2/53

Protective Effects of Oleoylethanolamide on Heart Alterations in a Rat Model of Diet-Induced ObesitySepe Christian (Rome), Friuli Marzia, Vergara Daniele, Eramo Barbara, Zahid Nisha, Panza Elisabetta, Bello Ivana, Giudetti Anna Maria, Romano Adele, Gaetani Silvana

P2/54

Targeting MASLD with Non-Psychedelic doses of Psilocybin: mechanistic and preclinical evidencesSignor Anna (Padua), Colognesi Martina, Gabbia Daniela, Rinaldi Andrea, Cascione Luciano, Alajati Abdullah, Saponaro Miriam, Guarato Giulia, Zanotto Ilaria, Frion-Herrera Yahima, Comai Stefano, Mattarei Andrea, Manfredi Paolo, De Martin Sara

P2/55

Targeting the Histaminergic system: a novel approach to preventing Binge-Like EatingTiti Costanza (Florence), Micioni di Bonaventura Emanuela, Costa Alessia, Sordi Virginia, Botticelli Luca, Einaudi Giacomo, Koziara Zuzanna, Passani Maria Beatrice, Cifani Carlo, Micioni di Bonaventura Maria Vittoria, Provensi Gustavo

Tuesday December 2nd, 2025

Sala Maggiore

Oral Communication Session 14

Neurodegenerative Diseases

Chairpersons: Fabrizio Gardoni (Milan), Maria Italia (Milan)

- 9.00-9.15 **Ca²⁺-storing organelles as druggable targets in astrocyte-neuron communication during Alzheimer's disease progression**
Piccirillo Silvia (Ancona), Preziuso Alessandra, Terenzi Valentina, Vinciguerra Antonio, Laricca Vincenzo, Castaldo Pasqualina, Magi Simona, Secondo Agnese
- 9.15-9.30 **Nrf2 Regulates Mitochondrial Ca²⁺ Transport in Physiology and Neurodegeneration**
Preziuso Alessandra (Ancona), Piccirillo Silvia, Dinkova-Kostova Albena, Abramov Andrey, Secondo Agnese
- 9.30-9.45 **Pharmacological modulation of mitochondrial metabolism to mitigate Alzheimer's disease neurodegeneration**
Serfilippi Tiziano (Ancona), Terenzi Valentina, Ciancio Raffaella, Piccirillo Silvia, Preziuso Alessandra, Magi Simona, Secondo Agnese, Laricca Vincenzo
- 9.45-10.00 **CAP2 gene delivery as a potential multi-target therapeutic approach for Alzheimer's disease**
Stringhi Ramona (Milan), D'Andrea Laura, La Greca Filippo, Zianni Elisa, Targa Lorenzo, Mosconi Cedric, Vandermeulen Lina, Ascagni Miriam, Speciani Michela Carola, Gardoni Fabrizio, Scheggia Diego, Edefonti Valeria, DiLuca Monica, Pelucchi Silvia, Marcello Elena
- 10.00-10.15 **Circulating MicroRNAs in Alzheimer's Disease: Pharmacological Implications for Novel Therapeutics and Treatment Monitoring**
Graziosi Agnese (Bologna), Sita Giulia, Ghelli Luca, Corrieri Camilla, Pilotto Andrea, Padovani Andrea, Morroni Fabiana, Hrelia Patrizia, Pani Arianna

- 10.15-10.30 **Dissecting dimethyl fumarate repurposing in alpha-synuclein-induced Parkinson's disease mouse model**
Salvadè Michela (Milan), Mancini Maria, Zianni Elisa, Italia Maria, Romito Elena, DiLuca Monica, Pisani Antonio, Gardoni Fabrizio
- 10.30-10.45 **Myocardial infarction activates neuroinflammation modulated by montelukast, disrupts oligodendrocyte homeostasis and alters microvesicle release kinetics**
Muluhie Majeda (Milan), Castiglioni Laura, Gelosa Paolo, Becchetti Alessia, Mercuriali Benedetta, Rzemieniec Joanna, Camera Marina, Sironi Luigi
- 10.45-11.00 **Neuroprotective Potential of *Punica granatum*: Attenuation of Oxidative Stress and DNA Damage in Human Neurons and Astrocytes**
Mazza Valeria (Catanzaro), Caminiti Rosamaria, Nucera Saverio, Ilari Sara, Passacatini Lucia Carmela, Marrelli Federica, Tucci Luigi, Trunfio Giuseppe, Oppedisano Francesca, Maiuolo Jessica, Mollace Vincenzo, Muscoli Carolina

Sala Artemisi

Oral Communication Session 15

Gender Pharmacology

Chairpersons: Elena Lucarini (Florence), Maria Antonietta Riemma (Naples)

- 9.00-9.15 **Impact of prenatal stress on mitochondrial function, metabolism, and inflammation in maternal, placental, and fetal brain tissues with sex-dependent differences**
D'Aprile Ilari (Milan), Petrillo Giulia, Marchesin Alessia, Begni Veronica, Riva Marco Andrea, Cattaneo Annamaria
- 9.15-9.30 **Chronic exposure to High-Fat Diet induces sex-specific neuropsychiatric vulnerability in young-adult mice**
Agosti Lisa Pia (Foggia), Cannata Alessia, Schiavone Stefania, Morgese Maria Grazia
- 9.30-9.45 **Sex-specific behavioral changes induced by chronic stress and effects of the rapid antidepressant ketamine in a mouse model of depression**
Mingardi Jessica (Milan), Nicosia Noemi, Giovenzana Mattia, Misztak Paulina, Aglioni Lucrezia, Musazzi Laura

- 9.45-10.00 **Sex differences in a mouse model of neuropathic pain: impact on cognitive, anxiety- and depressive-like dysfunctions**
Bove Maria (Foggia), Zafar Mohsin, Trisolini Samuele, Ghelardini Carla, Schiavone Stefania, Trabace Luigia
- 10.0-10.15 **Sex-Specific Impact of Vitamin D on Stereotypies and Immune Regulation in the BTBR Mouse Model of Autism Spectrum Disorders**
Palmieri Maria Adelaide (Foggia), Cordisco Annalisa, Bove Maria, Morgese Maria Grazia, Trabace Luigia, Gualillo Oreste
- 10.15-10.30 **Gender-dependent central and gut dysfunction in cuprizone-induced demyelination model**
Faggin Sofia (Padua), Fassina Elena, Zara Lucia, Nasini Sofia, Bosi Annalisa, Giaroni Cristina, Comai Stefano, Savarino Edoardo Vincenzo, Giron Maria Cecilia
- 10.30-10.45 **Gender differences in levodopa pharmacokinetics in patients with Parkinson's disease**
De Bellis Emanuela (Naples), Charlier Bruno, Corbi Graziamaria, Russillo Maria Claudia, Campana Federica, Izzo Viviana, Filippelli Amelia, Pellecchia Maria Teresa, Conti Valeria

Sala Felsina 1-2

Oral Communication Session 16

Clinical Pharmacology

Chairpersons: Maria Antonietta Barbieri (Messina), Arianna Pani (Milan)

- 9.00-9.15 **A Nomogram for the Prediction of Response to anti-CGRP mAbs: the CGRP Score**
 Romozzi Marina, Lokhandwala Ammar, Vollono Catello, Garcia-Azorin David, Vigani Giulia, De Cesaris Francesco, Altamura Claudia, Vernieri Fabrizio, Calabresi Paolo, Di Tella Sonia, Iannone Luigi Francesco (Modena)
- 9.15-9.30 **A prick is enough! Therapeutic drug monitoring of antiseizure medication through capillary microsampling devices**
Cancellerini Chiara (Bologna), Caravelli Alice, Esposito Erika, Soldà Martina, Vignatelli Luca, Mostacci Barbara, Fiori Jessica, Bisulli Francesca, Licchetta Laura

- 9.30-9.45 **Role of the clinical pharmacologist in the medication review and deprescribing: The experience of the Clinical Pharmacology unit of the University hospital of Salerno**
 Mazzeo Salvatore Maria, Martucci Alessandro, Pagano Annarita, De Stefano Alessandra (Salerno), Zarrella Adele, De Bellis Emanuela, Bilancio Giancarlo, Cardamone Chiara, Sisalli Laura, Amato Massimo, Triggiani Massimo, Sabbatino Francesco, Pepe Stefano, De Caro Francesco, Costantino Maria, Conti Valeria, Filippelli Amelia
- 9.45-10.00 **High-dose cefepime in critically ill patients: less is more?**
Agliardi Stefano (Milan), Gazzaniga Gianluca, Pani Arianna, Fumagalli Roberto
- 10.00-10.15 **Monitoring circulating tumor DNA levels as a prognostic tool to predict pathological response and relapse in Locally Advanced Rectal Cancer patients**
Giacomin Aurora (Aviano), Milan Noemi, De Mattia Elena, Scarabel Lucia, Ongaro Elena, Navaria Federico, Innocente Roberto, Gigante Marco, Belluco Claudio, Cecchin Erika
- 10.15-10.30 **Personalising adalimumab therapy in patients with juvenile idiopathic arthritis: definition of cut-off concentration for therapeutic drug monitoring and impact of the FCGR3A rs396991 genetic variant**
Dalla Zuanna Paolo (Trieste), Curci Debora, Klanjscek Marta, Pauli Giorgia, Lucafò Marianna, Franca Raffaella, Fabretto Antonella, Tommasini Alberto, Taddio Andrea, Arbo Anna, Pastore Serena, Stocco Gabriele
- 10.30-10.45 **UGT1A1*28 polymorphism does not predict neuropsychiatric drug toxicity in HIV-positive patients**
Pagano Annarita (Salerno), Donnarumma Danilo, De Bellis Emanuela, Mazza Ines, Manzo Valentina, Charlier Bruno, Corbi Graziamaria, Masullo Alfonso, Madonna Simona, Onofrio Mirella, Fortunato Valentina, Spera Anna Maria, Filippelli Amelia, Pagliano Pasquale, Conti Valeria
- 10.45-11.00 **Pharmacogenetics: a tool for new therapeutical approach in personalized medicine**
Pizzoleo Giulia (Trieste), Tesolin Paola, Curci Debora, Nardone Giuseppe Giovanni, Girotto Giorgia, Zudeh Giulia, Faleschini Michela, Stocco Gabriele, Fabretto Antonella

Sala Foyer

Oral Communication Session 17

Inflammation

Chairpersons: Gustavo Ferreira Alves (Camerino), Marco Gargaro (Perugia)

- 9.00-9.15 **Adenosine signalling modulation in UVB-induced melanogenesis and inflammation**
Plaitano Paola (Salerno), Giraulo Caterina, De Palma Giacomo, Cicala Carla, Morello Silvana
- 9.15-9.30 **CD27-CD70 signaling pathway as a new therapeutic target for the treatment of paediatric ulcerative colitis**
Muzzo Antonella (Trieste), Silvani Alessandra, Galli Michela, Grazioso Giovanni, Milano Erica, Valencic Erica, Bramuzzo Matteo, Decorti Giuliana, Stocco Gabriele, Lucafò Marianna
- 9.30-9.45 **Deciphering the time-dependent peripheral effects on brain dynamics in a mouse recovery model from DSS-induced colitis**
Opallo Nicola (Pavia), Comella Federica, Ciampi Clara, Pittaluga Anna Maria, Trabace Luigia, Meli Rosaria, Di Cesare Mannelli Lorenzo, Filibian Marta, Mattace Raso Giuseppina, Lanni Cristina
- 9.45-10.00 **Neurosteroids as Modulators of Microglial Activation and Neuroinflammation in Epilepsy: Toward a Novel Add-On Therapeutic Strategy**
Meanti Ramona (Milan), Sartori Emma, Criscione Maria Laura, Rizzi Laura, Bresciani Elena, Torsello Antonio Biagio
- 10.00-10.15 **Anti-Inflammatory Mechanisms of Pomegranate Extract in Human Cell Models**
Caminiti Rosamaria (Catanzaro), Mazza Valeria, Nucera Saverio, Ilari Sara, Passacatini Lucia Carmela, Marrelli Federica, Tucci Luigi, Trunfio Giuseppe, Oppedisano Francesca, Muscoli Carolina, Maiuolo Jessica, Mollace Vincenzo

- 10.15-10.30 **Chrysin-loaded calixarene-cyclodextrin ternary drug delivery system inhibits TGF- β and galectin-1 mediated pathways in diabetic liver fibrosis**
Lepre Caterina Claudia (Naples), Balta Cornel, Herman Hildegard, Ciceu Alina, Mladin Bianca, Rosu Marcel, Oatis Daniela, Russo Marina, Peteu Victor Eduard, Gherghiceanu Mihaela, Feryvesi Ferenc, Cotoraci Coralia, Trotta Maria Consiglia, D'Amico Michele, Hermenean Anca
- 10.30-10.45 **Antioxidant and anti-inflammatory effects of Sulforaphane and its metabolites: a comparative study in *in vitro* models**
Pagliarani Barbara (Bologna), Pruccoli Letizia, Tarozzi Andrea
- 10.45-11.00 **Effect of novel dual COX-2 inhibitors/TP antagonists on breast cancer cell invasion**
Ramaschi Giovanni Eugenio (Padua), Trevisi Lucia, Buccellati Carola, Sala Angelo, Bolego Chiara
- 11.00-11.30 Coffee Break

Sala Felsina 1-2

- 11.30-12.15 **Plenary Lecture**
 Chairpersons: Silvana Gaetani (Rome), Maria Antonietta Riemma (Naples)
- SMIT1 as a novel therapeutic target in cardiometabolic HFpEF**
 Alice Marino (Belgium)
- 12.15-13.00 **Closing Ceremony**

WITH THE UNCONDITIONAL CONTRIBUTION OF

Silver Sponsor



MENARINI
group

SERVIER 
moved by you

Bronze Sponsor

Lilly

WITH THE UNCONDITIONAL CONTRIBUTION OF

BIOLOGICAL INSTRUMENTS

AUROGENE
WE SERVE SCIENCE

 **Biogen.**

 **BiONOVA**
• TECHNOLOGIES


ERCOLAB
Consulting and Supply


Nikon


novo nordisk®


Roche

 **Springer Health**⁺

 **starlab**

TECNILABO
  
TECNIPLAST GROUP


Vinci-Biochem®

SPECIAL THANKS TO



In vitro innovative peptide-based biosensor as a diagnostic tool to identify JAKs tyrosine kinase activity in primary cells of pediatric patients affected by rare-immuno mediated diseases

Nicole Parmesan¹, Raffaella Franca², Letizia Pugnetti³, Paola Rispoli², Antonella Muzzo², Andrea Taddio^{2,4}, Alberto Tommasini^{2,4} and Gabriele Stocco^{2,3}

1. PhD School in Personalized Medicine and Innovative Therapies, University of Trieste, Trieste, Italy

2. Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy.

3. Department of Advanced Translational Diagnostics, Institute for Maternal & Child Health (I.R.C.C.S) Burlo Garofolo, Trieste, Italy

4. Department of Pediatrics, Institute for Maternal & Child Health (I.R.C.C.S) Burlo Garofolo, Trieste, Italy.

The aim of this study is the development of a peptide-based biosensor system to detect the aberrant JAKs activity in primary cells of pediatric patients affected by rare immune-mediated diseases and enrolled in the CONCERTO project (INTERREG VI-A Italy - Slovenia Programme 2021-2027). This project aims to enhance clinical outcomes of these children through clinicians cross-border collaboration and innovative biomedical approaches.

The system uses two published biotinylated peptide biosensors, P_{JAK2-S} or P_{JAK2-L}, which include specific tyrosine motif to detect the activity of JAK2^{1,2}. HEL and SET2 immortalized cell lines, which carry the JAK2 V617F gain-of-function mutation leading to a constitutive activation of JAK2, were used. Expression of JAKs protein and active phospho-proteins was confirmed in both cell lines in 1-mo stored lysates. A decrease of more than 60% of phospho-JAK2 was observed between ~2.5-mo vs ~3.5-mo stored lysates (One-way ANOVA, $p < 0.0001$). These results suggest that HEL and SET2 whole cell lysate should be used within 1-mo.

In order to gather experimental evidence that peptides are substrates of the catalytic domain of JAK2 (JAK2-JH1), the ADP-Glo™ Kinase Assay, a luminescent method to measure the ADP production after a kinase reaction, was performed. ADP was released when 2.5 ng/μl JAK2-JH1 was incubated with the peptide biosensors, achieving statistical significance for P_{JAK2-S} at 10 μM and P_{JAK2-L} at 20 μM (RLU basal phosphorylation of JAK2-JH1 versus 10 μM P_{JAK2-S} or 20 μM P_{JAK2-L} phosphorylation = median ± SEM = 21.0 ± 3.0 versus 190.3 ± 44.75 or 182.5 ± 18.06, respectively, both $p < 0.05$, two-way ANOVA, Bonferroni post-test). Notably, an increased in ADP detection could not be observed in the presence of P_{PHOSPHO-JAK2-L}, a phosphorylated form of P_{JAK2-L}, or with peptide probes specific for the ABL kinase, P_{JAK2-S} and P_{JAK2-L} are suitable peptide sequences for monitoring the activity of JAK2-JH1. Peptides phosphorylation was measured using a solid-phase ELISA assay using an antiphosphotyrosine primary antibody and a fluorescence detection, after exposing the peptides to full length JAK2 in cells lysated according to mild standard conditions³. Preliminary results did not show the phosphorylation of biosensor probes. More stringent lysis conditions were used to free the

JAK2 from any interacting protein. Again, biosensors were not phosphorylated above the baseline level of whole cell lysates or with JAK2 purified by immunoprecipitation, despite the presence of phospho-JAK2 confirmed in Western Blot. Significantly higher fluorescence values than baseline were observed for PPHOSPHO-JAK2, used as technical positive control for the ELISA assay ($P < 0.0001$, Two-way ANOVA, Bonferroni's post-test). As a further attempt we will enrich the active form of the kinase through immunoprecipitation with anti phospho-JAK2 antibody. If optimized, the peptide-based ELISA assay could be used on CONCERTO patients primary cells with JAK mutations.

1. Lipchik, A.M., et al., KINATEST-ID: a pipeline to develop phosphorylation-dependent terbium sensitizing kinase assays. *J Am Chem Soc*, 2015. **137**(7): p. 2484-94.
2. Sanz, A., et al., Analysis of Jak2 Catalytic Function by Peptide Microarrays: The Role of the JH2 Domain and V617F Mutation. *PLOS ONE*, 2011. **6**(4): p. e18522.
3. Montecchini O, Braidotti S, Franca R, Zudeh G, Boni C, Sorio C, Toffoletti E, Rabusin M, Tommasini A, Decorti G, Stocco G. A Novel ELISA-Based Peptide Biosensor Assay for Screening ABL1 Activity in vitro: A Challenge for Precision Therapy in BCR-ABL1 and BCR-ABL1 Like Leukemias. *Front Pharmacol*. 2021 Nov 19;12:749361. doi: 10.3389/fphar.2021.749361. PMID: 34867354; PMCID: PMC8640483.